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Zusammenfassung 
Prostatakrebs ist die zweithäufigste Todesursache unter den Tumorerkrankungen bei 
Männern. Ein aktuelles Modell für die Entstehung und Progression von Prostatakrebs muss 
eine Entzündung als Mitursache für die Entstehung von präneoplastischen oder 
neoplastischen Läsionen mitberücksichtigen. Der Polyomavirus BK (BKV) wurde schon mit 
Krebsvorstufen im Harntrakt assoziiert und spielt vermutlich eine wichtige Rolle in der 
Pathogenese des Prostatakarzinoms. 
Der onkogene Effekt von BKV scheint stark mit der Aktivität des Antigens Large T (L-
Tag) assoziiert zu sein, da dieses Antigen Tumorsupressorproteine zu binden und 
inaktivieren vermag. Dies gilt insbesondere für Proteine der Retinoblastoma Familie (pRB, 
p102 und p130) sowie p53. Der Mechanismus erlaubt es dem Virus, die infizierten Zellen 
während der produktiven Infektionsphase am Leben zu erhalten, was jedoch in nicht-
permissiven Zellen zur Onkogenese führen kann.  
Der Effekt des BKV L-Tag auf kritische Signalwege im humanen Zellzyklus, sowie der 
Nachweis von BKV und seine Expression in präneoplastischem Prostatagewebe veranlasste 
uns, die Rolle dieses viralen Antigens in der zellulären Immunüberwachung im 
Prostatakrebs zu untersuchen. Unsere Resultate unterstützen die These, nach der die CTL 
Immunantwort gegen virale Antigene effizient erhöht werden kann, wenn peptid-spezifische 
Memory T-Zellen eines seropositiven Individuums reaktiviert werden. In dieser Studie 
führten wir eine umfassende Analyse der CTL Antworten auf BKV large Tag Epitope in BKV-
positiven Patienten mit preneoplastischen oder neoplastischen Prostataläsionen durch. 
Ziel dieser Studie war es, die funktionellen Eigenschaften der BKV-spezifischen CTL 
Antwort in Patienten mit Prostatakrebs oder präkanzerösen Läsionen zu studieren. Als 
Kontrollpersonen wurden altersentsprechende Patienten mit Benigner Prostatahyperplasie 
sowie gesunde Kontrollpersonen jeglicher Altersgruppe untersucht. Wir identifizierten vier 
immunogene Peptide innerhalb des BKV L-Tag mit der Fähigkeit, eine spezifische Memory 
CTL Antwort zu reaktivieren. Zwei weitere Peptide, die in immunokompetenten BVK-
serpositiven Probanden bekanntermassen immunogen wirken, behielten ihre erwiesene 
Fähigkeit, die Immunantwort auf den Virus durch Verstärkung der tolerogenen Umgebung zu 
regulieren. Dies bestätigte teilweise die Hypothese, dass eine ineffiziente 
Immunreaktionsfähigkeit auf Antigene, die spezifisch durch onkogene Viren exprimiert 
werde, eine Rolle in der organspezifischen Tumorgenese und der darauffolgenden 
neoplastischen Progression spielen kann.  
Die Studie gibt einen vorläufigen Hinweis darauf, dass ein systemisches Boosting von 
Prostatakarzinompatienten mit immunogenen Domänen des BKV L-Tag eine T-Zell 
Immunantwort zugunsten einer effektiven proinflammatorischen Immunaktivität bewirkt. Dies 
  IV 
hebt die Immuntoleranz auf, die teilweise durch das BKV L-Tag induzierte regulatorische 
Profil gesteuert wird.  
  V 
Abstract 
Prostate cancer (PCa) is the third leading cause of cancer death in men. A 
contemporary model for prostate cancer induction and progression should include the 
potential contribution of inflammation to the development of preneoplastic or neoplastic 
lesions. The Human polyomavirus BK (BKV) has been associated to pre-early stages of 
cancer in urinary tract and it is postulated to play an important role in the pathogenesis of 
prostate cancer.  
The BKV oncogenic effect appears to be highly associated to the activity of the Large 
T antigen (L-Tag) because of its capability to bind and inactivate products of tumor 
suppressor genes, specifically tumor suppressor proteins of the retinoblastoma family (pRb, 
p107, and p130) and p53. This mechanism is used by the virus to keep the infected cells 
alive during the productive infection but in non-permissive cells it may lead to oncogenesis.  
The involvement of BKV L-Tag in the alteration of critical pathways of the human cell 
cycle together with its detection and expression in preneoplastic prostate tissues prompt us 
to investigate the role of this viral antigen as target of cellular immune surveillance in 
prostate cancer. Our data support the concept that CTL immune responses against viral 
antigens can be effectively expanded by reactivating peptide-specific memory T cells from 
seropositive subjects. In this study we propose a comprehensive analysis of CTL response 
against BKV large T antigen-related epitopes in BKV-experienced patients bearing prostate 
preneoplastic or neoplastic lesions irrespective of their HLA restrictions.  
The specific aim of this study was to fully characterize the functional features of BKV 
specific CTL responses in patients bearing prostate cancer or precancerous lesions, as 
compared to gender-matched controls (age-matched benign prostatic hyperplasia patients 
and non age-matched healthy donors). To this end we identified four immunogenic peptides 
within BKV L-Tag able to reactivate a specific memory CTL responses when challenged for 
their ex vivo and in vitro capability to recall CD4+ and CD8+ T cells. In addition, two peptides 
proven to be immunogenic in immunocompetent BKV seropositive subjects, maintained their 
known potential to regulate the immune response to the virus through the enhancement of a 
tolerogenic environment. This partially confirmed the hypothesis that an inefficient immune 
responsiveness to antigens specifically expressed by oncogenic viruses might play a role in 
organ specific tumorigenesis and subsequent neoplastic progression.  
This study gives preliminary evidence that a systemic boosting of PCa patients using 
immunogenic domains within BKV L-Tag would implement a T cell immune response in 
favor of an effective pro-inflammatory immune activity. This would lead to “the breaking of 
the immune tolerance” which is partially governed by BKV L-Tag in PCa.   
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1. Introduction 
1.1. The Prostate 
Prostate is an accessory reproductive gland of the male reproductive system. It 
surrounds the urethra and lies with its superior surface below the urinary bladder and with its 
inferior surface above the pelvic musculofacial floor. The dimensions of a healthy human 
prostate are similar to a walnut, with a weight around 20g. The prostate counts four distinct 
glandular regions, which represent the zonal anatomy classification. The peripheral zone 
(PZ) composes the 70% of the prostate volume, whereas the central zone (CZ) and the 
transitional zone (TZ) constitute the 20% and the 5%, respectively. The fourth zone is the 
fibro-muscular zone (or stroma), which accounts for the 5% of the prostate weight. In 
pathology, this classification is often used. Mostly cancers develop in the PZ, while benign 
hyperplasia does in the TZ of the prostate gland (McNeal, Redwine et al. 1988). The 
prostate is composed of fibromuscular stroma and of 30 to 50 glands surrounded by a thin 
layer of connective tissue, that drain into the prostatic urethra (McNeal 1972) (Blacklock 
1974) (McNeal, Redwine et al. 1988). 
The main function of the prostate is to secrete a milky, alkaline fluid into the urethra 
during ejaculation. This fluid constitutes 25-30% of the volume of the semen. Its function, 
exerted through its alkalinity, is to nourish, to protect and to increase the lifespan of sperm. 
The prostate also help expel semen during ejaculation. Another important function is 
controlling the flow of urine during ejaculation. 
The size and the function of prostate are regulated by hormones secreted by either the 
hypothalamic pituitary-testicular axis or adrenal gland. Testosterone, the main male hormone 
driving to anabolic and androgenic effects 
in men, is of great importance for the 
growth and maintenance of prostate gland. 
Products of testosterone catabolism targets 
specific DNA sequences leading to 
activation of cell functions, including cell-
growth and proliferation (Carlson and 
Katzenellenbogen 1990; Deslypere, Young 
et al. 1992) (Russell and Wilson 1994). 
 
Figure I - 1. The anatomy of prostate 
(From (De Marzo, Platz et al. 2007) 
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1.2. Prostate cancer 
1.2.1. Epidemiology 
Prostate cancer (PCa) represents the first leading cause of cancer morbidity and the 
third of cancer death in men in developed countries with a worldwide incidence rate 
accounting for 14% of total newly diagnosed cases and a worldwide total cancer mortality 
rate of 6% (Gonzalgo and Isaacs 2003) (Cooperberg, Moul et al. 2005; Jemal, Bray et al. 
2011). The most affected are African American men in the United States (SEER Program 
(National Cancer Institute (U.S.)), National Center for Health Statistics (U.S.) et al. 1993). 
Differences among populations might be caused by a combination of underlying aspects 
such as genetic susceptibility and differences in health care. Moreover, the importance of 
dietary, socioeconomic and environmental factors is illustrated by the increasing risk of PCa 
in Asian immigrants in the US (Whittemore, Kolonel et al. 1995). Genetic alterations probably 
also contribute to the huge geographical variation of PCa incidence.  
The PCa increasing incidence in industrialized countries might be due to the growing 
awareness of this disease and the more intense, refined and widespread diagnostic 
procedures, such as Prostate Specific Antigen (PSA) test and random biopsies (Potosky, 
Miller et al. 1995). In contrast, PCa mortality is declining owing to the improvement, as 
plausible explanation, in the management of this disease. Changes in PCa treatment include 
refinements in the techniques of radical prostatectomy and radiation therapy for early stage 
disease. It is likely that the more widespread use of these treatments is associated with 
increased numbers of men presenting with early stage disease, most of which probably 
detected through PSA screening.  
 
1.2.2. Etiology and risk factors 
Despite several research efforts, the cause of PCa remains unclear. It has been 
assumed that PCa has a multi factorial origin with environmental as well as genetic factors. 
To summarize, risk factors associated with increased incidence rate are: i) advanced age 
with an average age of 72 years at first diagnosis due to a longer life expectancy (the tumor 
is almost rare in 40-45 years old men); ii) family history of PCa (9% of PCa, genetically 
passed on in an autosomal dominant fashion); iii) race (African Americans develop PCa 50% 
more frequently than their Caucasian counterparts at the same age); iv) hormones activity 
(androgens and insulin-like growth factor); v) lower rate of daily dietary fibers and higher rate 
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of fat (Littrup 1997; Brawley 1998; Brawley, Knopf et al. 1998). 
Aging is the most relevant risk factor (Abate-Shen and Shen 2000). The mean age of 
patients diagnosed for PCa is 72-74 years, with about 85% after the age of 65. PCa is 
diagnosed rarely in people aged younger than 50 years (Sakr, Haas et al. 1993). Results of 
autopsy studies have reported that most men aged older than 85 years have histological 
PCa. Consequently, it has been suggested that most men would contract PCa if they live 
long enough (Sakr, Wheeler et al. 1996). 
The geographical incidence of PCa induced researchers to investigate its possible 
association with the western lifestyle and in particular diet that includes a high intake of fat, 
meat, and dairy products (Howell 1974). The results of these studies are mostly inconsistent, 
reflecting the complex multifactorial nature of this disease (Hayes, Ziegler et al. 1999) 
(Whittemore, Kolonel et al. 1995). However, several studies on animal model showed an 
over expression of AMACR (α-methyl-CoA remarcase) in PCa (Luo, Zha et al. 2002). This 
gene plays a key role in the metabolism of branched fatty acids, which is a potential source 
of carcinogenic oxidative damage. Because beef and dairy products are major sources of 
dietary branched fatty acids, up-regulation of AMACR might support the hypothesis of an 
association between “Western” diet and PCa. In addition, the western lifestyle has 
contributed to marked increase in the percentage of overweight and obese men over the last 
decades. Consequently, obesity has been considered a possible risk factor of PCa as well 
(MacInnis and English 2006). Results on this field are very contradictory, nevertheless some 
studies have shown an association between increased Body Mass Index (BMI) and risk of 
PCa mortality, suggesting that obesity might play a more important role in the progression of 
the disease than in its initiation (Rodriguez, Patel et al. 2001) (Rodriguez, McCullough et al. 
2003). Inflammation, arisen from exposure to environmental factors such as infectious 
agents and hormonal imbalances, is another risk factor that is likely involved in PCa 
development (De Marzo, Platz et al. 2007). Many others risk factors have been hypothesized 
and investigated, specifically the influence of occupation, sexual and physical activity and 
social factors (Bostwick, Burke et al. 2004). 
 
1.2.3. Cytogenetic 
Recurrent genetic aberrations in PCa have been documented over the last decade. 
The most frequent aberrations are losses in chromosomes 5q, 6q, 8p, 10q, 13q, 16q, 17p, 
and 18q, and gains in 7p/q, 8q, 9p, and Xq (Alers, Rochat et al. 2000). Target genes for 
these aberrations remain undefined mainly because of the heterogeneity of the disease 
(Amanatullah, Reutens et al. 2000). However, two genes for as many two chromosomal 
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aberrations have been identified: the androgen receptor (AR) at gene Xq12 and the 
TMPRSS2-ERG gene at 21q. The latter is a chromosomal translocation where the 
transcription factor related genes (ERG) is juxtaposed to androgen regulated type-2 
transmembrane serine protease (TMPRSS2) gene. It represents a recurrent gene fusion 
(TMPRSS2-EGR) occurring in up to 50% of clinically localized PCa (Tomlins, Rhodes et al. 
2005) (Tomlins, Mehra et al. 2006). Others putative target genes include: prostate-specific 
homeobox gene NKX3-1 - its loss expression correlate with tumor progression - (Bowen, 
Bubendorf et al. 2000) and Glutathione S-transferase P1 (GSTP1); its promoter-
hypermethylation is the most commonly described epigenetic alteration in PCa (DeMarzo, 
Nelson et al. 2003).The identification of target genes correlating to chromosomal aberrations 
in PCa will provide new prognostic markers and therapeutic targets for future drug 
development. 
 
1.2.4. Pathology of prostate cancer 
Prostate adenocarcinoma is the most common histological type among prostate 
cancers accounting for more than 90% of the cases (Cookson 2001). It usually arises from 
the active glandular epithelium along the periphery of the gland. PCa is an organ confined 
low risk cancer with low aggressive potential (usually, only 1 out of 6 PCa are lethal cancers 
 
 - Gleason score 8 to 10 at first diagnosis; 50% survival rate at 5 years). It has been 
reported that PCa at prostate intraepithelial neoplasia (PIN) stage (tumor size >0.5 cm3; 
Gleason score 2 to 4) progress to the level of overt cancer (tumor size of 3-4 cm3) in about 
10 years, and metastasize (preferentially in bone and brain) in about 15 years (Pound, 
Partin et al. 1999). Improvement of pre-emptive screenings (PSA test) has reduced the 
frequency of localized invasive cancers in patients at the time of first diagnosis with a 
 
Figure I - 2. Cellular model of early prostate neoplasia progression 
(From (De Marzo, Platz et al. 2007) 
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dramatic shift toward a “watchful waiting” treatment of choice. The latter has dramatically 
reduced source of tumor samples and limited the development of compelling research 
strategies, also owing to the intrinsic properties of PCa that render this tumor a difficult 
target (Schlomm, Erbersdobler et al. 2007). It has thus prompted researchers to focus on 
the identification of early stages of the tumor to better understand the mechanism 
responsible for PCa onset and progression.  
Despite the high prevalence and importance of PCa, the pathogenesis mechanisms 
underlying its development and progression remain poorly understood. It is supposed that 
transition from benign prostate over pre-neoplastic lesions to PCa is a continuous process 
(Bostwick and Brawer 1987). Several potential precursor lesions of PCa have been 
described, specifically low grade prostatic epithelial neoplasia, atrophy and atypical 
adenomatous hyperplasia.  
The proliferative inflammatory atrophy (PIA) of the prostate has recently gained 
relevance as potential precursor of prostatic intraepithelial neoplasia (PIN) and overt PCa 
(De Marzo, Platz et al. 2007), in particular owing to the prevalence of PIA in the peripheral 
zone of the organ, where usually histological transitions between PIA and PIN occur (De 
Marzo, Marchi et al. 1999; Putzi and De Marzo 2000) (Figure I - 2). However the most 
convincing data are those reporting high grade prostatic intraepithelial neoplasia (HGPIN) 
as precursor lesion of PCa (Montironi, Mazzucchelli et al. 2007). 
 
1.2.4.1. Proliferative inflammatory atrophy (PIA) 
Inflammation is a frequent finding in PCa. Many lesions containing inflammation are 
associated with either diffuse or focal epithelial atrophy. While most focal prostatic atrophy 
lesions have been considered to be quiescent, cells in some atrophy lesions appear 
proliferative. The term proliferative inflammatory atrophy (PIA) has been coined to define 
these proliferative glandular epithelial cells (De Marzo, Marchi et al. 1999). PIA lesions seem 
to arise in response to inflammatory injury caused by a variety of potential agents, among 
which infection (chronic bacterial infection, fungi, mycobacteria and latent viruses), cell injury 
(owing to exposure to chemical and physical trauma from urine reflux), hormonal variations 
and dietary factors.  
As documented by De Marzo et al., PIA may also emerge as a consequence of 
epithelial damage caused by oxidative stress. Oxygen radicals can directly damage DNA 
resulting in the accumulation of genomic aberrations. Moreover, modifications of specific 
genes may also be involved with elevated oxidative stress. For instance, Glutathione S-
transferase P1 (GSTP1) is a detoxification enzyme that helps to catalyze conjugation 
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reactions between potentially damaging oxidants and glutathione. GSTP1 is 
hypermethylated in more than 90% of PCa, this inactivation might leave cells vulnerable to 
oxidative DNA damage (Nakayama, Bennett et al. 2003). 
Many of the molecular and genetic changes seen in PIA are also documented in 
HGPIN and PCa. Morphological studies observed merging of focal atrophy with HGPIN and 
close relation to early carcinoma (De Marzo, DeWeese et al. 2004). In addition, PIA, HGPIN 
and PCa share similar locations in the prostate zones (McNeal 1988). As consequence of all 
these findings it has been postulated that PIA may represent precursor lesion to prostatic 
intraepithelial neoplasia and, therefore, prostatic carcinoma (De Marzo, Marchi et al. 1999). 
 
1.2.4.2. Prostatic intraepithelial neoplasia (PIN) 
The term prostatic intraepithelial neoplasia (PIN) was introduced by Bostwick and 
Braver in 1987. PIN is defined as an intra-acinar epithelial proliferation with significant 
nuclear atypia in the secretory cells (Bostwick 1988). The 3-tier grading system has been 
accepted to discriminate between low grade (LG) and high grade (HG) PIN. Low-grade (LG) 
PIN included grade 1 and high-grade (HG) PIN included grade 2 and 3. HGPIN may display 
a spectrum of 4 architectural patterns, which are: tufting, micropapillary, cribriform and flat. 
HGPIN and PCa are both multifocal and share similar locations in the prostate zones 
(Montironi, Mazzucchelli et al. 2000). HGPIN is strongly predictive of the presence of 
carcinoma; consequently the identification of HGPIN in biopsy has important clinical 
implications. PCa and HGPIN share several cytological features such as an increased 
proliferation and apoptosis (Montironi, Galluzzi et al. 1993), they are morphologically similar 
(Vis and Van Der Kwast 2001) and they have in common some molecular and genetic 
alterations (Qian, Jenkins et al. 1995). For all these reasons HGPIN is considered to be the 
most likely precursor of invasive PCa. 
 
1.2.5. Prognostic and predictive factors of PCa 
Prognostic factors characterize patients’ situations or conditions that can be used to 
estimate the chance of recovery from a disease or the chance of the disease recurring.  
Prediction of prognosis is one of the greatest challenges in tumor pathology (Burke, 
Bostwick et al. 2005). Despite all the efforts done to introduce new molecular biomarkers in 
the prediction of cancer prognosis, histopathological grade remains the most predictor factor 
for neoplastic diseases. 
Prognostic factors can be classified in three categories according to the College of 
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American Pathologist (CAP) (Bostwick, Grignon et al. 2000). The first category homes 
markers that are supported by robust data in the literature and are conventionally used in the 
management of patients. Considering PCa, preoperative PSA and histologic grade (Gleason 
score) belong to this category. These markers are used in clinical practice in the form of 
nomograms for prediction of tumor progression (Kattan, Wheeler et al. 1999). The second 
category includes markers that have been extensively studied at either biological or clinical 
level but with few clinical outcome data. In PCa, tumor volume and DNA ploidy belong to this 
category. The third category groups all markers that do not meet the criteria of category I or 
II. Examples are molecular markers of proliferation and angiogenesis, tumor suppressor 
genes, apoptotic genes and oncogenes, and more.  
Despite extensive research efforts, few biomarkers for PCa prognosis have been 
introduced to date in clinical practice. The clinical nomograms based on Gleason grade, 
tumor stage and serum level of PSA are still the best predictors of PCa outcome (Fiorentino, 
Capizzi et al.). However, the biotechnological advancements achieved in the last decade 
represent a remarkable source for new prognostic and predictive tissue and serum 
molecular biomarkers.  
 
1.2.5.1. Gleason score 
Donald F. Gleason worked on his grading system from 1960 to 1974. It has been 
developed by large patient population with long follow-up (Bailar, Mellinger et al. 1966) 
(Gleason 1966) (Gleason and Mellinger 1974) (Gleason 1988) (Gleason 1992).  
The Gleason score (GS) is today the grading system for PCa officially recommended 
by the World Health Organization (Eble JN 2004). PCa is graded according to Gleason 
system on specimen coming from needle biopsies, transurethral prostate resection (TUR-P) 
and radical prostatectomy (Brinker, Potter et al. 1999) (Brinker, Ross et al. 1999) (Amin, 
Boccon-Gibod et al. 2005) (Montironi, Lopez-Beltran et al. 2001) (Epstein, Srigley et al. 
2007) (Srigley, Amin et al. 2006). 
The Gleason score grading is based on the analysis of the glandular architecture of 
prostate tissue sections and does not take into consideration cytological features. The GS 
grading system accounts for five distinct patterns that prostate tumor cells tend to go 
through as they change from normal cells. The scale runs from 1 to 5, where 1 represents 
cells that are very nearly normal and 5 represents cells that don’t look much like prostate 
cells at all (Figure I - 3). The pattern determination is performed by visual estimation of 
tissue specimen under the microscope. The primary and secondary pattern (i.e. the most 
prevalent and the second most prevalent pattern) are added to obtain the GS (Gleason 
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pattern 1+ Gleason pattern 2). Obviously the score (sum) can range from 1 to 10. If the 
specimen has only one pattern, the GS is obtained by doubling that pattern. 
The strength of the Gleason score system lies in 
the fact that it is the most powerful predictor of patient 
outcome. It prevalently correlates with multiple other 
parameters related to prognosis, such as age 
(Draisma, Postma et al. 2006), serum PSA 
(Horninger, Rogatsch et al. 1999), clinical stage 
(Ramos, Carvahal et al. 1999) and pathological stage 
(Helpap and Egevad 2006). Moreover, it validity as 
independent effective prognostic factor for both 
prediction of natural PCa history and recurrence risk 
assessment after radical prostatectomy has been well 
documented (Berney, Fisher et al. 2007) (Han, Partin 
et al. 2003). 
The Gleason score system presents some 
weakness as well, mainly because of a pronounced 
clustering in the mid range pattern. A modification of 
the scoring system has been a long time debated. In 
2005 the International Society of Urological Pathology 
(ISUP) has solved this issue providing new 
recommendations for a modified Gleason system (Epstein, Allsbrook et al. 2005). Epstein JI 
has recently reviewed the modification introduced to Gleason score (Epstein). A schematic 
drawing of a modified Gleason system is depicted in Figure I - 3. The modified diagram 
shows the changes, which mainly involve pattern 3 and 4. 
 
1.2.5.2. Biomarkers in prostate cancer 
 
By definition, biomarkers are characteristics that are objectively measured and 
evaluated as indicators of normal biologic processes, pathogenic processes, or 
pharmacologic responses to therapeutic interventions. In prostate cancer, they should be   
specific and sensitive independent agents detectable either in blood or urine to discriminate 
between indolent and clinically significant cancers.  
So far, the relevant marker for diagnosis and therapeutic decision in PCa is the 
Prostate specific antigen (PSA). PSA is an enzyme produced by the cell of prostate gland to 
liquefy the semen. It can be detected in blood of patients (PSA cutoff≤4ng/ml). Together with 
 
Figure I - 3. Modified Gleason System 
(From (Epstein 2010) 
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the digital rectal examination (DRE) leads to patients’ therapeutic decision and serum PSA 
analysis contributes to patient stratification into different prognostic categories (Partin, 
Mangold et al. 2001). It is currently in use as marker for “active surveillance” (van den Berg, 
Roemeling et al. 2007) (Hugosson, Carlsson et al. 2010) and is a perfect indicator for PCa 
recurrence (0.02ng/ml on three consecutive blood tests) (Schmidt 2010). Although its 
effectiveness as prognostic factor PSA is associated with several limitations. The enzyme is 
organ but not cancer specific and can be influenced by several factors like prostate volume, 
patients’ age, treatment for benign prostatic hyperplasia (5-alpha-reductase-inhibitor). 
Indeed, relationship between serum PSA and patient outcome is influenced by coexisting 
prostatic hyperplasia (Beduschi and Oesterling 1997), patient age (Richardson and 
Oesterling 1997) and, eventually, Gleason grade (Partin, Carter et al. 1990). 
To date, molecular staging of PCa specimens was the only procedure available for 
PCa diagnosis, prognosis, and therapeutic decision. However, only a minority of studies 
carried out on PCa tissue specimens identified prognostic relevant markers, such as p53, 
Ki-67, Bcl-2 and AR, that correlated with clinical endpoints (Schlomm, Erbersdobler et al. 
2007). In addition, tissue specimens presuppose surgical interventions on patients as 
prostate biopsies or prostatectomy.  
To invest on PCa diagnosis and prognosis “before biopsies”, several efforts have been 
devoting on easy screening through the identification of specific biomarkers in human serum 
or urine, either at gene or protein level.  Among them, the PCA3 test is the relevant one. The 
test screens the release after prostate massage/DRE of a non-coding mRNA from DD3 
gene in urine of patients at risk of PCa. This non-functional gene is cancer specific, 
correlates with PCa positive biopsies and its production is independent of prostate volume 
and patients’ age. However, some weaknesses such as negative results in patients with 
PIN, correlation with Gleason grade and cancer volume render it not suitable as primary 
diagnostic test (Roobol, Schroder et al. 2010). The combination of two or more markers 
would enhance the sensitivity and specificity of screening tests. Indeed, a marker panel 
composed by PCA3, AMACR and the TMPRSS2-EGR gene, due to chromosomal 
translocation at 21q22.3, as multiplex gene test for PCa patients’ urine is currently in use. 
Targeting canonical markers and gene rearrangements might become an important 
innovative approach in solid tumors management. Taking advantage of new highly sensitive 
methodologies (DNA array, qRT-PCR, FISH, proteomics) would implement the number of 
predictive markers to test in universal and affordable easy screenings (Provenzano 2012).    
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1.3. Prostate cancer and viral association 
1.3.1. Human polyomavirus BK  
1.3.1.1. Etiology, epidemiology and clinical manifestation 
Human polyomavirus BK is a dsDNA virus belonging to the taxonomic family 
Polyomavirinae that comprises 13 distinct viruses with a common ancestor that exhibits a 
limited host range of host species to infect (Cole 1996). Human polyomaviruses are BKV, 
JCV, and the newly discovered polyomaviruses WUV (Washington University polyomavirus) 
(Gaynor, Nissen et al. 2007), KIV (Karolinska Institute polyomavirus) (Allander, Andreasson 
et al. 2007), and MCV (Merkel cell carcinoma polyomavirus or MCPyV) (Feng, Shuda et al. 
2008). They share approximately a 70-75% genome homology.  
Human Polyomavirus BK has been first identified in 1979 isolated from urine of a 
Sudanese patient (with initial B.K.) suffering from urethral stenosis after kidney 
transplantation (Gardner, Field et al. 1971). The BK virus is ubiquitous in the human 
population worldwide (Padgett and Walker 1976) establishing a life-long latent infection, 
except in some populations of Brazil, Paraguay and Malaysia (Brown, Tsai et al. 1975). 
Serological evidence indicates that nearly 90% of individuals are infected by early childhood, 
although a decrease in this rate (70-80%) during the human lifespan is reported (Taguchi, 
Kajioka et al. 1982).  
After primary infection the virus disseminates and establishes a latent infection in renal 
tubular epithelial cells and urothelial cell layers, the latter representing the principal site of 
viral latency (Imperiale 2000; Hirsch and Steiger 2003). It is also possible to detect BKV in 
liver, stomach, lung, lymph nodes (Israel, Martin et al. 1978; Pater 1980) and lymphocytes 
(Dorries, Vogel et al. 1994; Degener, Pietropaolo et al. 1997). The presence of BKV in 
tonsillar tissue (Goudsmit, Wertheim-van Dillen et al. 1982) suggests for respiratory tract as 
the initial site of viral replication. However, primary infection is thought to be asymptomatic 
although no specific upper respiratory symptoms have been noted in some individuals (Shah 
1996). The route of transmission may thus occur via respiratory secretions or exposure to 
urine (Major 2001). Spontaneous reactivations and low-level replication with shedding into 
urines is observed in 5-20% of healthy individuals (Hirsch 2005).  
Usually polyomaviruses cause persistent subclinical infections in humans and BKV 
infection rarely leads to clinical manifestation. Mild pyrexia, malaise, vomiting, respiratory 
illness, pericarditis and hepatic dysfunctions have been reported with primary infection 
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(Fioriti, Videtta et al. 2005). Reactivation in immune competent individuals with intermittent 
low-level urinary replication (BKV loads of ≤106/ml) and urinary viral shedding has been 
detected in 5% of infected subjects (Shah, Daniel et al. 1997). However, when the immune 
system is compromised, as following solid organ and bone marrow transplantation, HIV 
infection, chemotherapy or pharmacologic immune suppression, rate and level of BKV 
replication increase and may lead to organ disease (Gardner, MacKenzie et al. 1984; Leung, 
Suen et al. 2001; Hirsch, Knowles et al. 2002).  
Polyomavirus-associated nephropathy (PVAN) is the most challenging infectious in 
immune compromised kidney transplanted patients that leads to renal allograft dysfunction 
and graft loss (Hirsch and Steiger 2003; Hirsch 2005). BKV viral shedding in the urine is a 
useful test to exclude PVAN in kidney recipients (Comoli, Hirsch et al. 2008), although 
distinguishing between asymptomatic viral shedding in the urine of immune competent 
subjects (0.3%) and BKV disease (10%-45%) caused by viral reactivation (PVAN, ureteric 
stenosis, hemorrhagic cystitis) remains difficult (Fioriti, Videtta et al. 2005).  
Recent investigations have pointed out the role of viral non-coding control region 
(NCCR) variants in viral host cell permissiveness, rate of viral replication and type of disease 
diagnosed in BKV infected subjects (Gosert, Rinaldo et al. 2008). 
1.3.1.2. Viral structure and mechanisms of viral replication 
Human polyomavirus BK (BKV) is an on average 5 kilo base pairs (kbp) closed circular 
double-stranded (ds)DNA virus (5,153 bp for Dunlop strain (Dhar, Lai et al. 1978; Seif, 
Khoury et al. 1979) (Figure I- 1); 4,963 bp for strain MM (Tavis, Walker et al. 1989); 5,098 bp 
for strain AS (Yoshiike 1986)). BKV DNA is packaged as circular mini-chromosome in a 
complex with histone proteins (H2A, H2B, H3 and H4) and enclosed by a non-enveloped 
icosahedral capsid composed of three viral proteins (VP1, VP2, and VP3) (Eash, Manley et 
al. 2006).  
The genome of BKV consists of the hypervariable non-coding control region (NCCR) 
located between the genetically conserved coding regions for early genes and late genes. 
The NCCR drives viral gene expression. It contains, beyond the relevant cellular 
transcription factor binding sites, the origin for viral DNA replication (ori), promoter and 
enhancer for transcription of early and late genes and T antigens (Tags) binding sites (Cole 
2001; Moens 2001). The coding regions for early genes (L-Tag and small tumor antigen, s-
tag) are transcribed in a counter-clockwise direction while coding regions for late genes 
(agnoprotein, major structural protein VP1 and the two minor structural proteins VP2 and 
Introduction 
 17 
VP3) in a clockwise direction (Lednicky and Butel 1999). All proteins from each of the two 
coding regions are derived from a common precursor mRNA by alternate splicing. In 
particular, the early region is the first part of the viral genome to be transcribed and 
translated since encodes the two viral lifecycle regulatory L-Tag and s-tag. L-Tag has been 
identified early on as a key regulatory molecule interacting with infected cell cycle (Fanning 
and Knippers 1992). Differently, the role of s-tag in the lifecycle of polyomavirus is unknown 
and it has been given an ancillary role for L-Tag activity, such as increasing virus yield in 
permissive cell infection (Rundell and Parakati 2001).  
The infection cycle of BKV is divided into two phases: early and late. The first phase 
comprises viral entry and DNA replication while the second phase consists on assembly of 
new virions and release of viral progeny. Viral entry is governed by caveolae-mediated 
endocytosis (Eash, Querbes et al. 2004) that allows viruses to reach the nucleus of infected 
cells where their replication takes place (Drachenberg, Papadimitriou et al. 2003). Upon 
early viral gene transcription, L-Tag accumulation initiates viral DNA replication in the 
nucleus of infected cells by binding the NCCR ori region, promoting unwinding of DNA and 
recruiting the host cellular DNA polymerase and replication proteins (Imperiale 2007). Late 
genes expression encoding for structural proteins (VP1, VP2, and VP3) as well as 
expression of the regulatory agnoprotein, will follow. Viral assembly is achieved in the 
nucleus. The three viral structural proteins (VP1, VP2, and VP3) assemble with the 
 
 
Figure I - 4. Schematic organization of the human BK polyomavirus genome 
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replicated viral DNA to form virions that are released upon cell lysis (White and Khalili 2004). 
In the host species permissive cells, polyomavirus BK spreads by lytic infection. 
However, in non-permissive cells, in the context of an abortive infection, it leads to cellular 
transformation (White and Khalili 2004; White and Khalili 2005), although in the presence of 
activated oncogenes, such as c-Harvey-ras (Pagnani, Corallini et al. 1988), adenovirus E1A, 
c-rasA, c-myc (Corallini 2001). In particular, the two BKV early gene products L-Tag and s-
tag play a relevant role in cell immortalization and neoplastic transformation (Imperiale 2000; 
Imperiale 2001).  
As seen above, the role of L-Tag in the viral lifecycle is relevant for productive 
infections while the role of s-tag in this context is less unclear (Shenk, Carbon et al. 1976). 
Differently, L-Tag and s-tag cooperate in the transformation of infected cells (Martin, Setlow 
et al. 1979; Martin, Setlow et al. 1979; Porras, Bennett et al. 1996; Yu, Boyapati et al. 2001). 
L-Tag is a nuclear phosphoprotein that promotes cellular transformation by interacting with 
products of tumor suppressor genes: retinoblastoma (Rb) gene product (pRb), Rb family 
members p107 (Ewen, Xing et al. 1991) and p130 (pRb2) (Hannon, Demetrick et al. 1993), 
and wild-type p53 (Bocchetta, Eliasz et al. 2008), thus interfering with physiological check 
points of cell cycle (Tognon, Corallini et al. 2003; Ahuja, Saenz-Robles et al. 2005). L-Tag-
tumor suppressor gene products (thereafter referred as pRbs) binding modulates cellular 
signaling pathways that stimulate progression of infected cells into S phase in order to 
optimize the environment for viral replication (Fioriti, Videtta et al. 2005; Provenzano, Eliceiri 
et al. 2006). Therefore, this mechanism is used by the virus to keep infected cells alive 
during productive infection but in the context of non permissive cells it turns out into 
neoplastic transformation (Imperiale 2000).  
In details, L-Tag binds to pRb, p107, p130 competing with the transcription factors 
E2Fs (E2F-1 to E2F-8) for the re-phosphorylation of pRb, thereby interfering with E2Fs 
control activity and inducing infected cells to enter the cell cycle (S phase). In fact, pRbs-
E2Fs binding (E2F1, 2, 3a and 3b for pRb; E2F4 and E2F5 for p107 and p130) (Weinberg 
1995; Weinberg 1996) maintains pRb in a hypophosphorylated form in G0 and its 
phosphorylation during G1 to S progression is due to actions of mitogenic signals through 
cyclin-dependent kinases (Cobrinik 2005; Provenzano, Eliceiri et al. 2006). However, L-Tag-
pRb, p107, and p130 interactions are limited due to the low expressed levels of the BKV 
regulatory protein. Nevertheless, L-Tag alters phosphorylation patterns of pRbs members 
inducing serum-independent growth of infected cells (Harris, Chang et al. 1998; Harris, 
Christensen et al. 1998). Relevant is also the notion that polyomavirus L-Tag-pRbs binding 
is not stable during cell cycle phases (Ludlow, Shon et al. 1990).  
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Sequestration of p53 by L-Tag in the cytoplasm of infected cells represents the main 
step for their malignant transformation. The latter requires p53 inactivation to prevent: a) cell 
cycle arrest; b) DNA repair; c) cell apoptosis (Pipas and Levine 2001). The tumor suppressor 
p53 is able to mediate cell cycle arrest by inducing p21 expression, a cyclin-dependent 
kinase inhibitor (Xiong, Hannon et al. 1993)  that in turn causes cell arrest. It also drives to 
DNA repair in genetic damaged cells thus avoiding propagation of genetic mutations or 
aberrations to daughters’ cells (Bocchetta, Eliasz et al. 2008). L-Tag-p53 binding stabilizes 
the protein but inactivates its tumor suppressor function, thus mimicking the phenotypic 
effects caused by mutations in the p53 gene (Figure I - 5). The coexistence of BKV L-Tag 
and wild-type p53 in the cytoplasm of infected cells (Das, Shah et al. 2004) is a key point for 
supporting a BKV intervention in the genesis of human cancers (Das, Wojno et al. 2008). 
 
 
 
 
 
 
 
 
Figure I - 5. Interaction of BKV L-Tag with pRbs and p53 
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1.3.2. Association of BKV with human cancers 
1.3.2.1. Background 
The role of human polyomavirus in human cancers is still debated. Recent 
investigations have associated polyomavirus with the outgrowth of specific cancer types 
including colorectal cancer (Enam, Del Valle et al. 2002; Casini, Borgese et al. 2005), 
glioblastomas (Tognon, Casalone et al. 1996; Del Valle, Delbue et al. 2002), mesotheliomas 
(Carbone, Rizzo et al. 1997), prostate cancer (Das, Shah et al. 2004), lymphomas (Engels, 
Rollison et al. 2005; Rollison, Engels et al. 2006). Complete viral polyomavirus DNA genome 
or fragments containing the early region are able to transform embryonic fibroblasts and 
cells cultured from kidney or brain of mouse, rat, hamster, rabbit and monkey (Corallini 2001; 
Tognon, Corallini et al. 2003). It has rendered polyomavirus as prototypes of DNA tumor 
virus well amenable to studies in experimental models. However, the possible role for 
polyomavirus BK in human cancers is still controversial.  
In human, transformation of human cells by BKV is not efficient and often abortive 
(Tognon, Corallini et al. 2003) although BKV-infected or transfected cells show 
morphological alterations and increased lifespan (Grossi, Caputo et al. 1982). A complete 
transformed phenotype could be seen in human infected cells when they are in vitro 
transfected with recombinant DNA containing BKV early region genes (L-Tag) and 
oncogenes, such as c-rasA (pBK/c-rasA) or c-myc (pBK/c-myc), as seen in human embryo 
fibroblasts (Pater and Pater 1986) and adenovirus E1A (pBK/12-E1A) in human embryonic 
kidney (HEK) cells (Vasavada, Eager et al. 1986).  
So far, several scientific works examining the presence of BKV in human cancers 
using different techniques as polymerase chain reaction (PCR), immunohistochemistry 
(IHC), in situ hybridization (ISH) are available in the literature. Among them, some reported 
either BKV DNA, or viral RNA or proteins presence in the tumor specimens tested (Pagnani, 
Corallini et al. 1988; Imperiale 2000; Tognon, Corallini et al. 2003; White and Khalili 2004). In 
contrast, some other reports found no evidence for BKV in human tumors (Weggen, Bayer et 
al. 2000; Knoll, Stoehr et al. 2003; Bergh, Marklund et al. 2007; Lau, Lacey et al. 2007; 
Rollison, Sexton et al. 2007).  
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1.3.2.2. BKV and Prostate Cancer 
The proliferative nature of the prostate atrophy together with low rate of mutations 
detected in the tumor suppressor genes Rb1 and p53 of prostate cancer cells (Dong 2006), 
as compared to other tumors, has suggested for the involvement of an infectious agent that 
establishes a persistent subclinical infection in the urinary tract, such as polyomavirus BK 
(Das, Wojno et al. 2008). To sustain this hypothesis there are both the role played by 
human papillomavirus (HPV) oncoproteins E6 and E7 for the genesis of cervical cancer 
(Dyson, Howley et al. 1989; Choo and Chong 1993) and the discovery of BKV L-Tag-p53 
colocalization to the nuclei of bladder carcinoma cells (Geetha, Tong et al. 2002). On this 
regard, in an interesting study, Weinreb et al identified a population of patients with 
polyomavirus infected “decoy” cells in the urine (Weinreb 2006). The data correlate to the 
incidence of bladder cancer in those “decoy” cells positive patients thus leading to an 
association between polyomavirus and bladder cancer. In addition, Monini et al. 
demonstrated the presence of BKV sequences by PCR in more than 50% of both human 
urinary tract normal and tumor tissues, including prostate (Monini, Rotola et al. 1995). 
Immunohistochemical analysis of normal and atrophic epithelial prostatic cells using 
monoclonal antibodies specific to BKV L-Tag has shown that 60% of prostate tissues from 
healthy subjects are BKV positive as well as 71% of specimens from PIA. In particular, dual 
staining for L-Tag and p53 has been detected either in the nucleus or in the cytoplasm of 
PIA specimens but BKV L-Tag and p53 colocalization to the cytoplasm has been 
particularly seen in prostate cancer cells, while in L-Tag-negative tumors p53 staining was 
nuclear (Das, Shah et al. 2004). More recently, the same group has demonstrated that the 
p53 inactivation occurs in atrophic cells expressing wild-type p53 (Das, Wojno et al. 2008), 
finding promptly supported by other groups (Bocchetta, Eliasz et al. 2008).  
Imperiale’s group investigation fosters BKV as a cofactor in the etiology of PCa at 
early stages based on the following “hit-and-run” model: BKV infection of normal epithelial 
cells drive into PIA. At this level, expression of BKV is evident. The sequestration of wild-
type p53 induces infected cells to accumulate enough mutations to growth clonally without 
control. Both the dilution of BK viral episomes due to lack of replication and the immune 
selection of BKV infected cell against L-Tag are responsible for the loss of BKV in tumor 
cells (Das, Wojno et al. 2008). Although a low frequency of BKV L-Tag expression is 
reported by some authors (Zambrano, Kalantari et al. 2002; Balis, Sourvinos et al. 2007; 
Bergh, Marklund et al. 2007; Lau, Lacey et al. 2007), their data cannot exclude the 
possibility for a “hit-and-run” mechanism of BKV oncogenisis. Moreover, because of NCCR 
hypervariability in tissue cultures (Rubinstein, Schoonakker et al. 1991; Hanssen Rinaldo, 
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Hansen et al. 2005), genetically rearranged BKV variant might exist in the urinary tract and 
be responsible for neoplastic transformation in prostate cells (i.e. URO-1) (Shinohara, 
Matsuda et al. 1993). Thus, given the results obtained with prostate and bladder 
carcinomas, along with the kidney being the main site for BKV persistence, tumors of the 
urinary tract are the most logical target sites for an etiological association with BKV. 
1.3.3. BKV L-Tag and immune response 
During the course of viral infection the host immune response is of central importance 
in limiting the acute phase as well as in controlling the virus carrier state. The innate immune 
system is meant to act as a first line defense to prevent viral invasion and replication until 
development of specific adaptive immune response. Swanson P.A. et al. has recently 
reviewed the current understanding of the multifaceted immune response invoked by the 
mouse to face persistent infection in the polyoma virus-mouse model (MPyV) (Swanson, 
Lukacher et al. 2009). The mouse model of polyomavirus infection has demonstrated that 
virus control involves both humoral and cellular immune responses. Immunocompetent mice 
do not clear MPyV, with the virus likely persisting as infectious virus at low levels for the 
lifetime of the host. Nevertheless, without one or more arms of the adaptive immune 
response, MPyV infection proceeds unchecked, a consequence being tumor induction. 
Multiple components of the immune system contribute to limiting MPyV replication, including 
early induction of T-cell independent antibodies, recruitment of CD4+ and CD8+ T cells, and 
generation of T-cell dependent humoral immunity. Each of these components has the 
capacity to reduce viral load on its own, providing several layers of resistance to uncontrolled 
virus replication. Working together, they assure symptom-free survival with low-level viral 
persistence.  
Serological memory, defined as sustained antiviral antibody levels in the serum 
following infection, is crucial for protection against re-infection. In persistent infections, 
serological memory is also essential to check viral replication by decreasing the viral load. 
Two forms of B cell memory are generated in T-cell dependent humoral responses. B cells 
that have completed the germinal center reaction become either long-lived terminally 
differentiated plasma cells that migrate to the bone marrow where they continue to secrete 
antibodies, or they become memory B cells that reside in secondary lymphoid organs and 
can rapidly reactivate upon antigen re-stimulation (Ahmed 1992; Ahmed and Gray 1996).  
BKV-specific neutralizing antibodies are mostly directed against the major capsid protein 
VP1, rather than the minor capsid components, VP2 and VP3. Clinical observations suggest 
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that BKV-specific antibodies may accelerate clearance of primary infection and contribute to 
protection from BK viremia, but have a minimal role in the containment of polyomavirus-
related diseases (Comoli, Binggeli et al. 2006). 
The crucial role of T-cell immunity in the control of polyomaviruses infection was first 
suggested by the indirect evidence of increased incidence of reactivation and clinical 
disease linked to the degree of immune compromise. Specifically, it was demonstrated that 
cytotoxic T lymphocytes (CTLs) are critical for the clearance of acute polyomavirus infection 
in the mouse model, and for the containment of polyomavirus JC-associated progressive 
multifocal leukoencephalopathy in affected humans (Koralnik, Du Pasquier et al. 2002). 
Although CD4+ T cells are dispensable for CD8+ T cell expansion and function during the 
acute phase of the antiviral response, CD4+ T cells are essential for the generation and 
maintenance of long-lasting, functional memory CD8+ T cells (Sun, Williams et al. 2004; 
Kemball, Lee et al. 2006). Consistent with this model, there are far fewer MPyV-specific 
CD8+ T cells in persistently infected CD4+-depleted mice compared to wild type mice 
(Kemball, Pack et al. 2007).  
So far, the study of cellular immune response against BK virus reactivation has been 
limited to hematopoietic stem cell or solid organ (i.e. kidney) transplantations due to the 
relevant association between BKV reactivation upon immune suppression and polyomavirus-
associated nephropathy (PVAN) inducing allograft failures (Purighalla, Shapiro et al. 1995). 
Nevertheless, it has become more than ever evident, among immunologists and virologists, 
the principal role of T cell immune response in balancing BKV reactivation in latently infected 
cells since it has been seen that BKV-specific humoral immune response alone is inefficient 
in controlling virus reactivation and spreading and in containing BKV-related diseases 
(Comoli, Binggeli et al. 2006; Comoli, Hirsch et al. 2008). The finding has been of greater 
importance when a correlation between reductions of immunosuppressive treatments in 
PVAN transplanted recipients and decrease of BKV viral load in both plasma and urine along 
with an increase of frequency of IFN-γ-secreting lymphocytes was proved (Comoli, Azzi et 
al. 2004). Taking advantage of VP1 and L-Tag overlapping peptide pools and using as 
readout IFN-γ protein release measured by ELISPOT or flow cytometry assays, several 
studies have been devoted to the identification of a specific T-cell response to BKV antigens. 
(Zhu, Rice et al. 1992; Krymskaya, Sharma et al. 2005; Li, Melenhorst et al. 2006; 
Provenzano, Bracci et al. 2006; Randhawa, Popescu et al. 2006).  In particular, Hammer et 
al. described a relevant CD4+ and CD8+ T cell immune response in transplanted patients 
beyond a mandatory HLA restriction (Hammer, Brestrich et al. 2006).  
Since L-Tag mediated inactivation of p53 has been suggested to represent a critical 
step for BK viral oncogenicity, (Imperiale 2001; Tognon, Corallini et al. 2003) this antigen 
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has been identified as an important target for cancer immunity in murine models 
(Degl'Innocenti, Grioni et al. 2005; Otahal, Hutchinson et al. 2005). Early studies in SV40 
infected mice have reported on conserved CD8+ T cells immune responses against SV40 L-
Tag (Mylin, Schell et al. 2000). Within the BK virus-cell interaction modalities, L-Tag is thus 
the most highly expressed BKV antigen in non permissive infected cells and might 
encompass viral peptides generated by the MHC antigen processing pathway and, possibly, 
targeted by specific T cells epitopes. In addition, the L-Tag regions required for viral 
transformation, (pRbs domain aa91-120; p53 domains aa251-470 and aa521-640; almost 
80% of the entire sequence) are less likely to be mutated or lost, thus genetically conserved 
among polyomavirus strains (Velders, Macedo et al. 2001).  
A comprehensive understanding of the role of T cell immune response in balancing 
BKV activity is still demanding. The long-term maintenance of large numbers of specific 
memory CTL, due to the latency of BKV, with the ability of strongly facing viral infections 
might result in the clearance of the aggressor. Cellular immune response to BKV is important 
to define the specific antigenic pattern of the virus. Provenzano et al. have identified two 
HLA-A*0201-associated BKV L-Tag peptides able to effectively reactivate and expand a T 
cell memory peptide-specific response in BKV seropositive subjects. In particular, they 
reported that BKV specific CTL responders to portions of L-Tag exquisitely belong to a 
CD4+5RA+/CCR7+(-) CD8+ T cell population (Provenzano, Bracci et al. 2006). Notably, the 
study demonstrated for the first time that BKV seropositive subjects mount a powerful CTL 
response towards epitopes encompassed by highly phylogenetically L-Tag conserved 
regions implicated in the p53 mediated control of the cell cycle of host cells. 
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1.4. T-cell epitope mapping 
 
T-cell epitopes are defined as minimal essential peptide sequences derived from 
antigenic proteins which are required for recognition of T cells. This recognition is exerted by 
peptide binding to restricted MHC molecules on professional antigen presenting cells (APC), 
such as dendritic cells. 
Epitopes are thus antigenic portions of a protein and represent the basis for the 
understanding of adaptive immune response and for the development of preventive vaccines 
and peptide-based immunotherapies for viral and tumor diseases (Bui, Sidney et al. 2006; 
Sette and Peters 2007). They can be presented in the context of one or few MHC alleles. 
The latter supports the identification of promiscuous (i.e. presented by more alleles) (Ho, 
Mutch et al. 1990; Frahm, Yusim et al. 2007) and/or universal (i.e. presented by most of the 
alleles) (Panina-Bordignon, Tan et al. 1989; Letourneau, Im et al. 2007) antigenic peptides. 
 The precise identification of T-cell epitopes has been of importance for the diagnosis 
and treatment of infectious, allergic, autoimmune and neoplastic diseases (Akdis, Akdis et al. 
1996; Stienekemeier, Falk et al. 2001; Lauer, Ouchi et al. 2002; Lazoura and Apostolopoulos 
2005; Provenzano, Selleri et al. 2007; Leen, Christin et al. 2008). Identified epitopes within 
their specific restrictions have been collected to obtain peptide libraries that provide valuable 
diagnostic tools.  
T cell-epitope mapping selects candidate immunogenic HLA-specific peptides within 
antigenic proteins in order to create large libraries of HLA-restricted immune reagents that 
are valuable for patient and disease-specific clinical applications. Combinations of these 
peptides might theoretically fit all potential HLA restricting determinants upon validation of a 
documented immunogenicity. The past decade has witnessed the search for methodological 
approaches focusing on the identification of immunogenic peptides and their MHC 
associations. T-cell epitope mapping can be performed through static methodologies that 
involve tools, such as MHC-peptide multimers, to define the T-cell precursor frequency to the 
peptide or dynamic methodologies that analyze functional T-cell response upon peptide 
induction, such as cytokine gene expression and protein production, T cell proliferation, 
cytolytic T cell activity and T cell helper function (Kern, LiPira et al. 2005).  
Synthetic peptides used for epitope-mapping are generally represented by scrambling 
protein lysates or peptide pools containing longer sequences encompassing the protein at 8-
11 amino-acids pace (Reece, McGregor et al. 1994; Rodda 1996; Rodda 2002). However, 
investigations using the whole antigen are expensive, laborious and time consuming 
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procedures. To alternate the above attempts, the “in silico” prediction is the best start for this 
search and it is now preferred. This computational approach has improved dramatically 
since it was first developed by Berzofsky, Margalit, and DeLisi in the 1980s (DeLisi 1983; 
DeLisi and Berzofsky 1985; Margalit, Spouge et al. 1987) and always leads to successful 
identification of immunogenic peptides. The concurrent use of different prediction algorithms 
is not only informative on the likelihood of individual peptides to be processed and presented 
within specific HLA restrictions but it is also able to predict with low margin of error the 
immunogenic potential of specific sequences. The in silico prediction might also ease the 
straightforward peptide-pool approach restricting peptide panels by deleting those peptides 
that have been predicted as poor binders.  
The majority of methods for predicting MHC-peptide binding are available for public 
use (Figure I – 6). They are classified in two groups: methods generated from sequences of 
peptide binders (sequence-based models), and those that do not require any peptide binding 
data and are based on the sequence and structure of MHC molecules (modeling-based 
methods). Sequence-based models can also be divided in two types: those based on 
qualitative data that describe the ability of peptides to bind to MHC molecules (binders and 
non-binders) and those trained on quantitative data consisting of peptides whose binding 
affinity for MHC molecules has been determined. Qualitative models try to recognize the 
binding pattern that is present on the peptides used for training (binding pattern recognition 
models), whereas quantitative regression models target the prediction on the actual binding 
affinities of known peptides to MHC molecules (quantitative binding affinity models).  
Despite the prediction of MHC-peptide binding is the basis for anticipating T cell 
epitopes, it considers all virtual peptides derived from arbitrary cleavage of the protein 
sequence. The anticipation of peptide fragments that can be actually produced through the 
intracellular antigen processing can be of remarkable relevance. To that, information from 
proteolitic activity of the immunoproteasome (protein cleavage into short peptides), peptide 
transporter (TAP) activity, selection of peptides fitting the groove of MHC molecules and the 
formation of trimeric complexes (peptide/MHC/β2-microglobulin) into the lumen of the 
endoplasmic reticulum (ER) have been modeled and considered for their potential 
applications for antigen following a HLA class I related endogenous processing (i.e. tumor or 
viral antigens) (Larsen, Lundegaard et al. 2005) (Brusic, Bajic et al. 2004). Many algorithms 
have been thus developed combining those information. For instance, one of the best 
available database integrating proteasomal cleavage, TAP-transport and MHC-binding is the 
Immune Epitope Data Base (IEDB, http://tools.immuneepitope.org) (Peters, Sidney et al. 
2005; Peters and Sette 2007; Vita, Peters et al. 2008; Vita, Zarebski et al. 2010). 
Nevertheless, MHC-binding prediction, although supported by overall antigen processing 
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data, does not guarantee in itself that a T-cell bearing such specificity is present indeed in 
the T-cell repertoire.  
MHC class II binding predictions are not as well developed as that of MHC class I 
binders (Nielsen, Lund et al. 2010). In general, antigenic presentation by HLA class II 
molecules is employed for peptides following and endocytic processing. Usually, the 
MHC/peptide complex takes place into cell compartments generated by fusion of early 
endosomes, transporting the antigenic protein after its phagocytosis/endocytosis, and 
primary lysosomes operating antigenic degradation and containing the MHC molecule. In 
contrast to MHC class I, the peptide-binding groove of MHC class II molecules is open (the 
MHC class II-bound peptides vary widely in length; 9-22 residues), consequently MHC class 
II molecules impose relatively weak limitations on peptide side chains, harboring broader 
peptide binding repertoires than MHC class I molecules. These qualities hardly set the 
generation of reliable peptide binding models for MHC class II molecules (Madden, Gorga et 
al. 1992; Matsumura, Fremont et al. 1992; Barber and Parham 1993).  
In conclusion, T-cell epitope mapping allows identifying immunodominant regions on 
antigenic proteins. Since methodological approaches currently in use require extended 
peptide panels and large amounts of T cells, many efforts have been making to develop high 
throughput techniques, reducing the size of experimental conditions and increasing the 
sensitivity of the detection of the functional response. In silico prediction of immunogenic 
peptides combined with in vitro and in vivo verifications can simplify and accelerate the 
identification process of T-cell epitopes   
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Figure I - 6. Freely Available Servers for Public Prediction of MHC-Peptide Binding 
(From (Lafuente and Reche 2009) 
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2. Purpose 
The aim of this dissertation was the identification of immunogenic peptides within BKV 
Large T antigen capable to strongly elicit adaptive memory immune responses to the virus in 
prostate cancer patients (PCa), irrespective of specific HLA associations, in order to define 
the level of immunogenicity of these sequences in pre-early and early stages of the disease. 
We attempted the characterization of an antigen-specific competent immune 
surveillance in BKV seropositive PCa patients, gender- and age-matched BPH, gender-
matched but not age-matched healthy donors by comparing functional features of peptide 
expanded CD4+ and CD8+ T cells  
The implementation of a L-Tag-specific T cell immune response that favors effective 
pro-inflammatory activities against BKV in PCa patients might set the stage for original 
controlled investigations on mechanisms that allow BKV involvement in prostate cancers. It 
might also provide sound scientific bases for the application of a wide range MHC peptide-
vaccination in either preventive or therapeutic settings.  
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3.4.1. Materials and Methods 
Donors and patients accrual and HLA genotyping 
Twenty-nine consecutive patients diagnosed for either prostate cancer (PCa, n=19; 
Robot-assisted Laparoscopic Radical Prostatectomy) or benign prostate hyperplasia (BPH, 
n=10; Transurethral Resection of the prostate, TUR-P) were enrolled upon informed 
consent, as approved by the Ethical Committee of Zürich (KEK). All patients received post-
surgical care at the Department of Urology, University Hospital of Zurich and relevant clinical 
data were collected by retrospective review of the patients’ files. In addition, we collected 
blood (buffy-coats, Blutspende Zürich) from gender but not age-matched healthy donors 
(HDs, n=13).  
A complete, high resolution, HLA genotyping (HLA-A*, HLA-B* and HLA-DRB1*) was 
performed by PCR with allele-specific sequencing primers (PCR SSP Protrans) according to 
the manufacturer’s specifications. 
Peptide selection, design and synthesis 
Four major algorithms, IEDB (http://www.immuneepitope.org/home.do) (Vita, Zarebski 
et al. 2010), Bimas (http://www-bimas.cit.nih.gov/molbio/) (Parker, Bednarek et al. 1994), 
SYFPEITHI (http://www.syfpeithi.de) (Rammensee, Bachmann et al. 1999) and NetMHCII 
(http://www.cbs. dtu.dk/services/NetMHCII) (Nielsen, Lundegaard et al. 2008; Nielsen and 
Lund 2009) were employed to “in silico” predict the eleven HLA class II restricted BKV L-Tag 
candidate immunogenic peptides used in this study (human polyomavirus BK, strain 
Dunlop). Peptides were synthesized by GL Biochem Ltd. with purity ranging from 90% to 
100%, as analyzed by high-performance liquid chromatography, dissolved in 100% Dimethyl 
Sulfoxide (DMSO) and stored at –70°C until use. 
.PepMixes™ based on complete protein-spanning mixtures of overlapping peptides 
(lengths: 15aa, overlap: 11aa), such as BKV L-Tag peptides pool and HIV (B gag motif) 
peptides pool or PepMixes™ Cytomegalovirus/Epstein-Barr/Flu (CEF) peptides pool of 23 8-
11mer peptides recognized by CD8 positive T cells and presented by 11 class I HLA-A and 
HLA-B alleles, were synthesized by JPT Peptide Technology (Berlin, Germany) and used as 
positive and negative controls. In addition, Phytohaemagglutinin (PHA) (Sigma Aldrich) and 
tetanus toxin universal T cell epitope (P2tt830-843) were used to test the integrity of our 
peptide screening. 
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Enzyme immunoassay (EIA) 
BKV specific antibody detection  in donor and patients sera was performed by enzyme 
immunoassay (EIA) with GST-BKV fusion protein, as reported in Leuenberger et al 
(Leuenberger, Andresen et al. 2007). Optical densities were measured using an automated 
plate reader (Tecan Group Ltd.) at 492 nm (OD492). Affinity-purified GST was run as a 
negative control and subtracted from the GST-BKV L-Tag domain 1 (LTD1) signals. For 
every sample, the OD was determined by subtracting the corresponding GST background. 
The cut-off was defined as two standard deviations as above mean values of the negative 
controls. Therefore, all OD values <0.04 were considered negative. For confirmatory testing, 
we included three selected samples as references, (negative; <0.04, borderline positive; 
<0.1 and strongly positive; >0.1), indicating variation coefficients of <10%, which can cause 
minimal shifts in the groups.  
Quantitative RT-PCR for BKV DNA detection 
DNA from urine and serum of patients was extracted using the QIAamp DNA Mini Kit 
(Qiagen) according to the manufacturer’s instructions. The genome detection of 
polyomavirus BK was performed by qRT-PCR using a TaqMan assay targeting L-Tag. The 
assay, named T3a, consist of a primer/probe set which has been designed to reliably 
measure BKV L-Tag subtypes Ia, Ic, III, IV and VI (Hoffman, Cook et al. 2008). PCR 
amplification was set up according to standard real-time PCR protocols using a Corbett life 
science Rotor-gene 3000 instrument (Corbett Life science). Standard curves for the 
quantification of BKV L-Tag were generated using serial 10-fold dilutions of plasmid 
pBKV35-1 DNA (LGC Standards Sarl). For the purpose of this study, the limit of detection 
was arbitrarily set at 2 log copies/mL 
T lymphocytes collection, separation and in vitro expansion 
Peripheral blood mononuclear cells (PBMCs) isolated from venous blood of patients 
and donors by Ficoll-Hypaque density gradient centrifugation were resuspended in RPMI 
medium supplemented with 100µg/ml Kanamycin, 10mM Hepes, 1mM sodium pyruvate, 
1mM Glutamax and non-essential amino acids (all from GIBCO Paisley), hereafter referred 
to as complete medium, supplemented with 5% human serum (Blutspende Zürich, 
Universitätsspital Zürich, Switzerland). For in vitro culturing T cells were plated in complete 
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medium with 5% human serum in 24-well plates at a final concentration of 1x106 cells/ml and 
were co-cultured (37°C, 5% CO2 atmosphere) with autologous irradiated (750 sec in a 
gamma ray irradiator equipped with a Co radiation source emitting 100 rad/min) antigen 
presenting cells (APCs) previously pulsed for 4h with peptides (10µg/ml), either for priming 
(day 0) or for rounds of re-stimulation.  
IFN-a dendritic cells were used as APCs (hereafter referred as IFNDCs). Briefly, 
CD14+ cells were purified from PBMCs by magnetic cell separation (Miltenyi Biotech) 
according to producers’ protocols. Cells were then cultured at a final concentration of 
1.5x106 cells/well for 3 to 4 days in complete medium supplemented with 10% foetal calf 
serum, 0.004% mercaptoethanol, rhIFN-α (100000 UI/ml) and recombinant human 
granulocyte macrophage-colony stimulating factor (GM-CSF; 50 ng/ml) to generate mature 
IFNDCs. 
 Recombinant human (rh) IL-2 (Hoffmann-LaRoche) was added to the cultures at 
1ng/ml, 1ng/ml and 5ng/ml, on days 3, 7 and 10, respectively. Cells were re-stimulated with 
specific peptide in the presence of irradiated APCs on day 7 of culture.  
 
 
Antigenic stimulation and qRT-PCR analysis 
Ex vivo induction of peptide-specific responses was attempted as follows. Briefly, 2 × 
105 isolated PBMCs from patients and donors were incubated in 96 U-bottom well plates in 
200 µl of complete medium supplemented with 5% human serum. After an overnight resting, 
each of the eleven L-Tag peptides selected by “in silico” prediction was in turn used to ex 
vivo stimulate (1 µM) the cells for 4 hours. As controls, BKV-L-Tag peptides pool, 
Phytohaemagglutinin (PHA), Tetanus toxin universal T cell epitope (P2tt830-843), and 
Cytomegalovirus/Epstein-Barr/Flu peptide-pool (CEF) were also used.  
Total RNA extraction and cDNA synthesis were carried out following manufactures’ 
instructions (MagMAX™-96 for Microarrays Total RNA Isolation Kit, AMBION and High 
Capacity cDNA Reverse Transcription Kit, Applied Biosystem). Quantitative real-time PCR 
(qRT-PCR) assays were performed as previously described on a Rotor-gene 3000 detection 
system (Corbett Life Science) using TaqMan® gene expression PCR Master Mix Reagents 
Kit and sets of primers and probes (Applied Biosystems) from cytokine genes (IFN-γ, TNF-α, 
IL-2, IL-10, TGF-β1), lytic machinery components (Granzyme, Perforin) and factors 
regulating cytolysis/apoptosis (Fas-L and PD-1).  
The 2-ΔΔCt method [ΔΔCT = (CT, cytokine – CT,β-actin)induction – (CT, cytokine – CT,β-
actin)baseline, where CT is the mean cycle times of the triplicate well readings] was employed to 
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compute fold changes of cytokine gene expression. The HIV peptide-pool with B gag motif 
was used as negative control to provide the baseline allowing the ΔΔCT calculation. An 
endogenous reference gene (β-actin) was used to normalize target gene expression. Two-
fold increase was the threshold for significant fold changes.  
Cytokine intracellular staining and T-cell phenotype 
Peptide expanded PBL (1x106) were rested overnight and then stimulated with 5 x104 
peptide-pulsed (10 µg/ml) IFNDCs. Two hours after induction, 1µg/ml of Brefeldin A (Sigma 
Aldrich) was added to the culture. For CD107 detection, anti-CD107a antibody (BD 
Biosciences) was added at the beginning of the stimulation in the presence of GolgiStop (BD 
Biosciences) (1µg/ml). After four additional hours, cell incubation was stopped by washing 
cells with cold phosphate-buffered saline (PBS). Pellets were re-suspended in 1 ml PBS 
containing 1 mM EDTA and 0.5% FCS and cells were stained extracellularly with 10 µl of 
fluorescent mAbs against CD4+, CD8+, CD25, CD45RA, CD62L, CD69 (BD Bioscience) for 
15 min at 4°C in the dark. Cell fixation was performed with 2 ml of BD FACS Lysis Solution 
(BD Bioscience), according to the producers’ instructions. Cellular permeabilization was 
performed by re-suspending cells in 500 µl of FACS Permeabilizing Solution 2 (BD 
Bioscience) at 1:10 dilution in Diethyl Pyrocarbonate (DEPC) water, at room temperature for 
10 min. For intracellular staining, either 5µl of human anti-IFN-γ or 5µl of human anti-IL-2 
mAbs were used as test and mouse IgG1 isotype-(BD Bioscience) was used as control. 
Cells were then incubated for 30 min at 4°C in the dark. Samples were acquired on a 
FACSCalibur flow-cytometer (BD Bioscience) and analyzed by Flowjo software (Tree Star).  
Monoclonal T-Cell Sorting Using an IFN-γ Secretion Assay 
Two-week L-Tag peptides in vitro cultured CD8+ and CD4+ T cells were re-challenged 
with autologous APCs pulsed with relevant peptides or control pool at a ratio of 1:2 for a 
maximum of 5 h. Cell surface detection of IFN-γ-secreted molecules was performed 
according to the manufacturer’s instructions (Miltenyi Biotech) as follows. Briefly, cells were 
labeled for 5 min at 4°C with an IFN-γ-specific high-affinity capture matrix (bispecific Ab-Ab 
conjugate directed against CD45 and IFN-γ). Cells were then transferred into a 37°C warm 
medium for 45 min to permit secretion of IFN-γ, washed and stained for 30 min at 4°C with 
PE-labeled anti-IFN-γ mAb (Miltenyi Biotech). Subsequently, cells were washed and 
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magnetically labeled for 15 min at 4°C with anti-PE Ab microbeads (Miltenyi Biotec) and PE-
labeled IFN-γ secreting cells were enriched through two rounds of positive selection by 
magnetic cell sorting (Miltenyi Biotech) to generate peptide-specific oligoclones to use for 
functional assays. Part of each sample was analyzed by flow cytometry to assess the 
viability of CD4+ and CD8+ IFN-γ secreting T cells. 
LDH release cytotoxic assay 
The cytotoxic activity of IFN-γ secreting T-cell oligoclones was measured using lactate 
dehydrogenase (LDH) release assays (Promega). As target cells, peptide- or control pool-
pulsed autologous IFNDCs were cultured withCD4+ or CD8+ T cell suspensions at 50:1, 
20:1, 10:1, 5:1 and 1:1 effector:target (E:T) ratio, in triplicate and incubated at 37°C, 5% CO2 
atmosphere for 6h. Thereafter, 100 µl/well supernatant was carefully removed and 
transferred into corresponding wells of an optically clear 96-well flat bottom microplate. 100 
µl reaction mixtures was added to each well and incubated for 25 min at room temperature 
in the dark. Absorbance at 490 was measured using a microplate enzyme-linked 
immunosorbent assay reader. The percentage of specific lysis was calculated as follows:  
(experimental release - spontaneous release)/ (maximum release - spontaneous 
release)*100. Maximum release was obtained by adding 100 µL of lysis solution to the 100 
µL medium containing target cells. Spontaneous release was consistently less than 15% of 
maximum release in all assays. 
Statistical analysis 
All data were analyzed using SPSS data editor 19 and Graph Pad Prism 5.0 statistical 
software. Data were reported as mean ± S.D. or median and ranges where appropriate. 
Differences between two groups were analyzed using Student’s t-tests. Differences between 
more than two groups were analyzed using repeated measures ANOVA and Bonferroni’s 
multiple comparisons as a post hoc test. Two sided p-values of < 0.05 (CI 95%) were 
considered statistically significant. 
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3.4.2. Results 
3.4.2.1. Peptide sequences characterization and algorithm predictions 
To identify candidate immunodominant peptides within Large T antigen (Table III - 1) 
we used an in silico prediction methodology that takes into account peptide processing 
(immuno-proteasome cleavage and TAP transport) and HLA-binding affinity. We thus 
employed different algorithms, such as the Epitope Database and Analysis Resource 
(IEDB), SYFPEITHI, Bimas and NetMHCIIpan Database.  
HLA class I binding affinity was then analyzed by combining IEDB, SYFPEITHI and 
Bimas datasets, giving priority to peptides with higher affinity. We thus selected nonamer 
(9mer) peptides with the highest probability to bind HLA class I molecules within at least 34 
subtypes (15 HLA-A and 19 HLA-B). The predicted IEDB output is given in units of IC50nM. 
Therefore, peptides with IC50 values <50 nM bear high affinity, <500 nM intermediate affinity 
and <5000 nM low affinity properties, respectively. Bimas scores nonamer (9mer) and 
decamer (10mer) peptides according to their half-time disassociation from the HLA binding 
groove, while SYFPEITHI considers the amino acid positions as anchor residues for peptide 
binding to its corresponding HLA molecules.  
Based on score datasets, we were able to select several HLA-A and B restricted 9mer 
peptides predicted to be immunogenic. Interestingly, the majority of these 9mer peptides 
were amino acid sequences nested, in number of 3 or higher, in same regions of the L-Tag, 
thus characterizing, by tiling at 2 to 4 amino-acid pace, putative HLA class II restricted 
peptides (Table II-1). Therefore, eleven 15-18mer peptides (BK1 L-Tag27-41, BK2 L-Tag69-85, 
BK3 L-Tag148-164; BK4 L-Tag172-185, BK5 L-Tag196-209, BK6 L-Tag212-226, BK7 L-Tag398-414, BK8 
L-Tag410-426, BK9 L-Tag521-537; BK10 L-Tag531-545, BK11 L-Tag570-587) were those nesting the 
highest numbers of HLA class I restricted potentially immunogenic 9mer peptides.  
We then considered these regions for HLA class II binding affinity by employing 
NetMHCIIpan and IEBD databases. Prediction was run on a total of 13 HLA class II loci. In 
brief, in the IEDB database, four methods (ARB, combinatorial library, SMM_align and 
Sturniolo) provide peptide scores and percentile rank of each 9mer core sequence identified 
in larger putative peptides (usually 15mer sequences selected by the algorithm) in relation to 
the HLA allele the prediction was made. Prediction is generated by comparing the peptide's 
score against the scores of five million random 15mer peptides selected from SWISSPROT 
database. The median percentile rank of the four methods is then used to generate the rank 
for consensus score.  A small numbered percentile rank indicates high affinity. NetMHCIIpan 
method is used to calculate consensus score when other methods, such as SMM_align, 
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and/or Sturniolo are not available for a particular HLA allele. Differently, NetMHCIIpan is 
used as second or third choice.  
 
3.4.2.2.  HLA typing, BKV L-Tag serology and molecular testing in 
donors and patients 
A complete high resolution HLA class I and II genotyping was performed by sequence-
specific PCR using genomic DNA. HLA specificities for class I alleles, loci A and B, and for 
class II alleles, locus DRB were considered (Table II-2).  
Humoral response against BKV L-Tag was tested in blood serum of both patients and 
donors.  BKV L-Tag IgG seroprevalence was observed in 16/19 (84.21%) patients with PCa, 
in 9/10 (90%) patients with BPH and 10/13 (76.92%) HDs. We also tested BK viral load in 
urine (viruria) and in sera (viremia) of same individuals by using real-time polymerase chain 
reaction targeting L-Tag. Asymptomatic BK viruria was observed in one patient (PCa-196: 
854 copies/ml), whereas it was absent in all BPH patients and donors with available urine 
(n=4). Similarly, BK viremia was detected in one patient (PCa-9: 218 copies/ml) (Table II – 
2). 
3.4.2.3. Systemic cellular immune response upon BKV L-Tag peptide-
pool induction 
In order to define the systemic cellular immune response against BKV L-Tag in both 
groups of patients, as compared to gender- but not age-matched HDs, we tested cytokine 
gene expression upon ex vivo antigenic stimulation by using the BKV L-Tag PepMix (a 
complete protein-spanning mixture of 170 15mer overlapping peptides at 11 amino-acid 
pace). Freshly isolated PBMCs of 16 patients with PCa, 10 patients with BPH and 10 HDs 
were 4-hour ex vivo stimulated with L-Tag peptide-pool, Phytohaemagglutinine (PHA), and 
Cytomegalovirus/Epstein-Barr/Flu peptide-pool (CEF). The HIV peptide-pool with B gag 
motif was used as negative control to provide a baseline allowing the calculation of cytokine 
gene expression fold changes. A panel of gene encoding pro-inflammatory (IFN-γ, TNF-α) 
and regulatory (IL-10, TGF-β1) cytokine was used as readout.  
T cell immune reactivation is generally observed in individuals carrying positive 
antibody activity against viral antigens they have experienced when portions of those 
antigens (peptides) are used to both ex vivo and in vitro recall specific cellular immune 
responses. Thus, testing patients and donors accrued, cytokines gene expression upon L-
Results 
 107 
Tag peptide-pool induction exceeded the arbitrary threshold level of 2-fold in all the BKV L-
Tag seropositive subjects, as compared to BKV L-Tag seronegative counterparts (Figure II-
2), thus confirming the integrity of our experimental approach that identify specific antigenic 
reactivation in seropositive subjects upon short-time ex vivo inductions.  
According to peculiar differences observed between proinflammatory and regulatory 
cytokine gene expression upon L-Tag peptide-pool stimulation, in particular IFN-γ (PCa 
patients: mean±SD: 1.33±0.97, median: 1; BPH patients: mean±SD: 1.8±1.3, median: 2) and 
IL-10 (PCa patients: mean±SD: 4.4±3.5, median: 2.1; BPH patients: mean±SD: 2.5±3.4, 
median: 1) (Figure II-3), a systemic differential pattern of immune responsiveness seems to 
be fostered by L-Tag in seropositive PCa patients (n=13, p=0.004) but not in seropositive 
BPH patients (n=9, p=0.59), despite a pro-inflammatory impairment, considering both IFN-γ 
and TNF-α gene expression, was seen in both groups of patients. As expected, a pro-
inflammatory cytokines gene expression significantly exceeded a regulatory cytokine gene 
expression (IFN-γ: mean±SD: 13.2±15.3, median: 6.7; IL-10: mean±SD: 1.6±10.7, median: 
1.8; p=0.048) in L-Tag peptide-pool induced seropositive HDs (n=8) (Figure II-4). In addition, 
the relevant pro-inflammatory cytokine gene expression seen in PCa patients after 
stimulation with control peptide-pool CEF (IFN-γ: mean±SD: 14.30±19.6, median: 5.54) 
better stress that the cytokine skew due to L-Tag cannot be merely ascribed to physiological 
decline of immune fitness frequently occurring in elderly individuals (Figure II-3).  
An additional analysis of the regulatory cytokine TGF-β1 expression upon L-Tag 
peptide-pool stimulation did not corroborate IL-10 gene expression data, although some 
samples were positive for TGF-β1 gene expression in both PCa patients (mean±SD: 
2.3±2.14, median: 2) and BPH patients (mean±SD: 1.97±2.2, median: 1.62) (p=0.74) (Figure 
II-3). 
 
3.4.2.4. Ex vivo immune responsiveness to confirm the potential 
immunogenicity of in silico predicted L-Tag peptides 
To determine whether portions of L-Tag, such as single peptides, could confirm or 
revert the skewed immune responsiveness observed in patients upon L-Tag peptide-pool 
induction, the eleven in silico selected peptides were employed to characterize T cells 
responses upon their stimulation on freshly isolated PBMCs from same accrued patients and 
donors (see 3.4.2.3). The tetanus toxin universal T cell epitope (P2tt830-843) was included 
among the positive controls used in this study. Transcript productions of relevant pro-
inflammatory (IFN-γ, TNF-α) and regulatory (IL-10, TGF-β1) cytokine were thus compared 
among groups of patients and healthy donors.  
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Four peptides out of the eleven predicted to be immunogenic (BK1 L-Tag27-41; BK4 L-
Tag172-185; BK6 L-Tag212-226; BK10 L-Tag531-545) induced a significant pro-inflammatory immune 
response (as detected by IFN-γ and TNF-α gene expression) in about half (49.2%) of BKV 
seropositive PCa patients (BK1 L-Tag27-41: 45%, mean 4 ± 5.7, median 1.8 folds; BK4 L-
Tag172-185: 54%, mean 2.2 ±1.5, median 2 folds; BK6 L-Tag212-226: 54%, mean 4.4 ± 6.7, 
median 2.3 folds; BK10 L-Tag531-545: 44%, mean 3.4 ± 3.8, median 1.8 folds) (Figure II – 5) 
and in almost 70% of gender-matched HDs (mean 66.75%; range 55-78%). Of relevance, no 
significant concomitant induction of regulatory cytokines (IL-10 and TGF-β1) was detected 
(PCa patients: BK1 L-Tag27-41: 23%, mean 1.5 ± 1, median 1 folds; BK4 L-Tag172-185: 20%, 
mean 1.4 ± 0.8, median 1 folds; BK6 L-Tag212-226: 12%, mean 1.8 ± 4.4, median 1 folds; BK10 
L-Tag531-545: 10%, mean 1.9 ± 3.7, median 1 folds) (Figure II – 6). Similar data, although at 
lesser non significant extent, were obtained from BPH patients (pro-inflammatory gene 
expression (pge): mean 40%; range 35-45%; regulatory gene expression (rge): mean 20%; 
range 15-25%; data not shown).  
Two peptides, BK7 L-Tag398-414 (pge: 27%, mean 1.93 ± 1.87, median 1.13 folds; rge: 
61%, mean 3.01 ± 2.66, median 2.2 folds) and BK11 L-Tag570-587 (pge: 31%, mean 1.67 ± 
1.47, median 1.1 folds; rge: 54%, mean 4.69 ± 7.56, median 2.1 folds) confirmed the cytokine 
skew observed in PCa patients upon L-Tag peptide pool induction (Figure II – 5/6). Notably, 
two 9mer peptides, BK L-Tag406-414 and BK L-Tag579-587, nested within BK7 L-Tag398-414 and 
BK11 L-Tag570-587, respectively, have been previously see by us to trigger an immune-
regulatory T cell response in PCa patients (Sais et al: data not shown), whereas they were 
documented to induce pro-inflammatory responses in BKV seropositive healthy donors 
(Provenzano, Bracci et al. 2006).  
In addition to BK1 L-Tag27-41, BK4 L-Tag172-185, BK6 L-Tag212-226 and BK10 L-Tag531-545, 
three more peptides, BK3 L-Tag148-164, BK8 L-Tag410-426 and BK9 L-Tag521-537, were able to 
specifically recall immune response, but only in HDs.  
 
 
3.4.2.5. Phenotypic characterization of IFN-γ- and IL-2-producing BKV 
pL-Tag expanded T cells 
Cytokine gene expression data indicated that BK1 L-Tag27-41, BK4 L-Tag172-185, BK6 L-
Tag212-226 and BK10 L-Tag531-545 peptides were able to efficiently ex vivo recall immune 
activity in both seropositive patients and healthy donors. To gain insight into functional 
features of peptide-specific T cells reactive against BKV L-Tag, both freshly isolated CD4+ 
and CD8+ T cells from same patients with PCa and healthy donors were 2-week peptide in 
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vitro expanded. Patients bearing BPH were excluded due the weak cytokine gene 
expression detected in all individuals reacting to each of the four peptides, as compared to 
HDs. Cytokines production was then analyzed according to cell phenotype. Stimulation was 
performed with a mini-pool consisting of BK1 L-Tag27-41, BK4 L-Tag172-185, BK6 L-Tag212-226 
and BK10 L-Tag531-545 (hereafter referred as pL-Tag). We considered as positive response 
any pL-Tag-induced cytokine production (IFN-γ and IL-2) exceeding 3-fold the background 
(2-week in vitro expansion with pL-Tag and re-challenging with HIV peptide-pool).  
Eight subjects (5 PCa patients and 3 HDs) showed pL-Tag-specific CD4+ T cells, as 
defined by IFN-γ production, and among them five (4 PCa patients and 1 HD) showed pL-
Tag specific CD8+ T cells. Percentage of IFN-γ-producing CD4+ T cells ranged from 0.8 to 
8.6% (mean 3.1±2.5%, median 2.6%) (Figure II – 7A), while percentage of IFN-γ-producing 
CD8+ was less relevant and ranged from 0.54 to 1.44% (mean 1.1±0.4%, median 1.2%) 
(Figure II – 7B).  
CD62L and CD45RA are markers in use to characterize CD4+ and CD8+ T cells 
phenotype. Indeed, four distinct T-cell subsets can be described: CD45RA+ CD62L+high 
(naive), CD45RA– CD62L+high (TCM: central memory), CD45RA– CD62L+low /CD62L- (TEM: 
effector/memory) and CD45RA+ CD62L+low /CD62L- (TEMRA: effector/memory) (Seder and 
Ahmed 2003) (Lefrancois and Marzo 2006) (Sallusto, Geginat et al. 2004). In our analysis, 
IFN-γ-producing CD4+ and CD8+ from either PCa patients or HDs were found to belong to 
the effector memory T cells subpopulation. Among them, IFN-γ-producing CD8+ T cells from 
two PCa patients showed a clear CD45RA+ TEMRA phenotype (Figure II – 8, 9).  
To determine the effector function of pL-Tag-specific IFN-γ producing CD4+ and CD8+ 
T cells, CD107a expression was used to evaluate their cytolytic potential. CD107a is a 
lysosomal-associated membrane protein that has been described as a marker of CD8+ T-
cell degranulation following stimulation. It is expressed on the cell surface after lysosomal 
membrane fusion and it is a necessary precursor of cytolysis (Betts, Brenchley et al. 2003). 
In this specific setting, both pL-Tag-expanded IFN-γ-producing CD8+ and CD4+ T cells 
showed a significant increase in surface mobilization of CD107a, as compared to IFN-γ 
negative peptide-stimulated counterparts (Figure II – 8, 9) and in accordance to significant 
degranulation following mitogenic (PHA) stimulation (Figure II-10).  
Given the decisive role of helper T cells in the optimal expansion of CTLs, we also 
assayed the ability of pL-Tag to induce and expand IL-2-producing CD4+ T cells. As 
expected, all batches of cells from either PCa patients or HDs that were responsive to pL-
Tag-induction (n=8) were IL-2-producing CD4+ T cells with the peculiar helper phenotype 
(CD25+ CD69+) (Figure II – 8).  
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3.4.2.6. Functional features and peptide-specific HLA restrictions of 
CTL polyclones generated from single IFN-γ secreting T cells   
In order to identify cognate recognition of each of the four peptides contained in the pL-
Tag (BK1 L-Tag27-41, BK4 L-Tag172-185, BK6 L-Tag212-226 and BK10 L-Tag531-545), pL-Tag in 
vitro induced T lymphocytes were re-challenged with single peptides and both killing 
phenotype and killing activity were performed. Thus, two-week in vitro expanded CD4+ and 
CD8+ T cells with a significant mobilization of CD107a upon pL-Tag induction (CD4+/pL-
Tag/Pca-196, CD4+/pL-Tag/PCa-223, CD4+/pL-Tag/HD-GS and CD8+/pL-Tag/PCa-196) 
showed the following peptide-specific T cells responses: CD4+/BK1 L-Tag27-41/Pca-196, 
CD4+/BK10 L-Tag531-545/PCa-223, CD4+/BK6 L-Tag212-226/HD-GS and CD8+/BK4 L-Tag172-
185/Pca-196 (Figure II - 11). Therefore, we generated CTL polyclones sorting IFN-γ secreting 
T-cells from each batch of T cells responsive to single peptide stimulation, as reported 
above, and evaluated their capability of exerting cytotoxic activity on peptide-pulsed 
autologous IFNDCs. Three CTL polyclones generated by IFN-γ-secreting T cells (CD4+/BK1 
L-Tag27-41/Pca-196, CD4+/BK6 L-Tag212-226/HD-GS, and CD8+/BK4 L-Tag172-185/Pca-196) 
exerted cytotoxic activity with a delta specific lysis (ΔSL) >40% at 10:1 ratio, whilst 
CD4+/BK10 L-Tag531-545/PCa-223 at 10:1 ratio did not reach 20% (Figure II – 12A).  
Cells were in parallel analyzed for the expression of genes encoding molecules 
mediating cytotoxicity. Three CTLs mediated cytotoxic mechanism were considered: 
exocytosis of lytic proteins (perforin, granzymes), receptor-ligand binding (Fas-L) and TNF-α 
mediated cytolysis/apoptosis. As shown in Figure II -12B, there was a significant expression 
of granula-dependent factors (perforin and granzyme) and receptor-mediated cytotoxic 
effectors molecules in all CTL polyclones tested. In addition, to settle CTLs exhaustion, we 
tested the expression of programmed death 1 receptor (PD-1). We could detect significant 
expression of PD-1 in none of the CTL polyclones analyzed, thus confirming their potential to 
retain functional activity after rounds of restimulations.  
In conclusion, owing to algorithm predictions (Table II - 1) and HLA class I and II 
typing, as previously reported in Table II - 2 (PCa-192: HLA-A*0101/0301, HLA-
B*0701/1301, HLA-DRB1*0101/0401; PCa-196: HLA-A*0201/0201, HLA-B*0801/5101, HLA-
DRB1*0101/1101; PCa-223: HLA-A*0201/1101, HLA-B* 4001/4401, HLA-DRB1*0701/1201; 
HD-GS: HLA-A*0201/6801, HLA-B*5101/5501, HLA-DRB1*0401/1401) we were also able to 
restrict the four peptides to specific HLA molecules: HLA-DRB1*0101/BK10 L-Tag531-545, 
HLA-DRB1*1101/BK1 L-Tag27-41, HLA-DRB1*0401/BK6 L-Tag212-226 and HLA-A*0201/BK4 L-
Tag172-185. 
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Figure II - 1. Structure and amino acid sequence of polyomavirus BK Large Tumor Antigen 
The p53 binding domains are shown in magenta and the pRb binding region is highlighted in red. 
(3D immage adapted from (Lilyestrom, Klein et al. 2006) PDB ID: 2H1L). (NCBI reference sequence: YP_717940.1) 
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Table II - 1. Candidate immunodominant peptides within L-Tag and their HLA class I/II associations 
(i) HLA restriction has been assigned according to the predicted affinity score (IEDB for class I and 
NetMHCII for class II) given in nM IC50 values. 
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Table II - 2. HLA typing, BKV L-Tag serology, viruria and viremia of PCa patients, age- and gender-
matched BPH patients and non-age-, gender-matched healthy donors 
(i) IgG vs L-Tag (OD): (-) < 0.04; (+) < 0.1; (++) > 0.1 
(ii) BKV L-Tag DNA molecular testing: (-) < 2 log copies/ml  
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Figure II - 2. Cytokines gene expression profiling in PCa patients, BPH patients and HDs upon 
stimulation with a pool of overlapping peptides spanning the entire BKV L-Tag sequence 
Ex vivo analysis of pro-inflammatory (IFN-γ and TNF-α) and immune regulatory (IL-10 and TGF-β1) cytokine 
patterns in PCa: n=16, BPH: n=10 and HDs: n=10 upon BKV L-Tag peptide-pool induction, as compared to a 
viral specific peptide-pool (CEF) induction. Peptide-induced cytokine genes expression was assessed after 4-hr 
incubation. Data are reported as cytokine gene relative quantification (2-∆∆Ct). HIV peptide-pool was used as 
negative control to provide a baseline to compute fold changes. An arbitrary cut-off (dotted line) was set at 2-
fold. BKV seronegative individuals are shown as red dots. 
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Figure II - 3. Cytokines gene expression profiling of BKV seropositive subjects upon stimulation with 
a pool of overlapping peptides spanning the entire BKV L-Tag sequence 
Ex vivo analysis of pro-inflammatory (IFN-γ and TNF-α) and immune regulatory (IL-10 and TGF-β1) cytokine 
patterns in PCa: n=16, BPH: n=10 and HDs: n=10 upon BKV L-Tag peptide-pool induction, as compared to 
stimulation with a viral specific peptide-pool (CEF) and PHA. Peptide-induced expression of the indicated 
cytokine genes was assessed following 4-hr incubation. Data are reported as cytokine gene relative 
quantification (2-∆∆Ct). HIV peptide-pool was used as negative control to provide a baseline to compute fold 
changes. An arbitrary cut-off (dotted line) was set at 2-fold.  
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Figure II - 4. Differential pattern of immune responsiveness in BKV seropositive patients and donors 
triggered with a pool of overlapping peptides spanning the entire BKV L-Tag sequence  
Ex vivo analysis of pro-inflammatory (IFN-γ and TNF-α) and immune regulatory (IL-10 and TGF-β1) cytokine 
patterns in PCa: n=16, BPH: n=10 and HDs: n=10 upon BKV L-Tag peptide-pool induction. Peptide-induced 
expression of the indicated cytokine genes was assessed following 4-hr incubation. Data are reported as 
cytokine gene relative quantification (2-∆∆Ct). HIV peptide-pool was used as negative control to provide a 
baseline to compute fold changes. An arbitrary cut-off (dotted line) was set at 2-fold.  
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Figure II - 5. Pro-inflammatory gene expression as detected in BKV seropositive PCa patients and 
healthy donors upon single BKV L-Tag peptides. 
Analysis of pro-inflammatory (IFN-γ and TNF-α) cytokines gene expression in BKV seropositive PCa patients 
(n=16) and HDs (n=10) following ex vivo BKV L-Tag single peptides stimulation. Peptide-induced cytokines 
gene expression was assessed following 4-hr incubation. Three control peptides were used to compare 
mitogenic (PHA), viral-specific (CEF) and unspecific (P2tt830-843) antigenic stimulation. Data are reported as 
cytokine gene relative quantification (2-∆∆Ct). HIV peptide-pool was used as negative control to provide a 
baseline to compute fold changes. An arbitrary cut-off (dotted line) was set at 2-fold. Interquartile min to max 
was reported for cytokines gene expressed upon induction. Only responses exceeding the cut-off (2-fold) were 
considered positive. (HDs: clear boxes; PCa patients: Dotted boxes).  
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Figure II - 6. Regulatory gene expression as detected in BKV seropositive PCa patients and healthy 
donors upon single BKV L-Tag peptides. 
Analysis of regulatory (IL-10 and TGF-β1) cytokines gene expression in BKV seropositive PCa patients 
(n=16) and HDs (n=10) following ex vivo BKV L-Tag single peptides stimulation. Peptide-induced cytokines 
gene expression was assessed following 4-hr incubation. Three control peptides were used to compare 
mitogenic (PHA), viral-specific (CEF) and unspecific (P2tt830-843) antigenic stimulation. Data are reported 
as cytokine gene relative quantification (2-∆∆Ct). HIV peptide-pool was used as negative control to provide a 
baseline to compute fold changes. An arbitrary cut-off (dotted line) was set at 2-fold. Interquartile min to max 
was reported for cytokines gene expressed upon induction. Only responses exceeding the cut-off (2-fold) 
were considered positive. (HDs: clear boxes; PCa patients: Dotted boxes).  
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Figure II - 6. Immune responsiveness of CD4+ and CD8+ T cells triggered by pL-Tag 
Purified CD4+ and CD8+ T cells were stimulated with autologous IFNDcs loaded with pL-Tag in the presence 
of IL-2. On day 14, cells were harvested and re-challenged using autologous IFNDCs pulsed either with pL-
Tag or a control pool of irrelevant peptides (HIV). IFN-γ was measured in a standard ICS assay. 
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Figure II - 7 Functional and phenotypic characterization of pL-Tag induced CD4+ T cells 
Representative ICS of pL-Tag induced IFN-γ (A) and IL-2 (D) production from five BKV seropositive individuals 
(three PCa patients and two HDs). Purified T cells were cultured for 2 weeks in presence of pL-Tag-pulsed 
autologous IFNDCs. On day 14, cells were harvested and re-challenged with either pL-Tag or a control pool of 
irrelevant peptides (HIV). Quadrants were set based on an isotype control. Data reported in the quadrants 
referred to percentages of CD4+ T cells showing evidence of cytokines production. 
(B) CD107a expression for both IFN-γ producing (filled histogram) and IFN-γ negative (open histogram) CD4+ T 
cells was analyzed. The percentage of positive cells was indicated in each plot based on isotype control (dotted 
histogram). (C; E) Cytokines producing CD4+ T cells were stained either with CD45RA and CD62L (IFN-γ+ 
CD4+ T cells) or CD25 and CD69 (IL-2+ CD4+ T cells). 
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Figure II - 8 Functional and phenotypic characterization of pL-Tag induced CD8+ T cells 
Representative ICS of pL-Tag induced IFN-γ (A) production from four BKV seropositive individuals (three 
PCa patients and one HD). Purified T cells were cultured for 2 weeks in presence of pL-Tag-pulsed 
autologous IFNDCs. On day 14, cells were harvested and re-challenged with either pL-Tag or a control pool 
of irrelevant peptides (HIV). Quadrants were set based on an isotype control. Data reported in the quadrants 
referred to percentages of CD8+ T cells showing evidence of cytokines production. 
(B) CD107a expression for both IFN-γ producing (filled histogram) and IFN-γ negative (open histogram) 
CD8+ T cells was analyzed. The percentage of positive cells was indicated in each plot based on isotype 
control (dotted histogram). (C) IFN-γ producing CD8+ T cells were stained with CD45RA and CD62L. 
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Figure II - 9 Analysis of CD107a expression in pL-Tag induced IFN-γ+ T cells 
Comparative MFI analysis of CD107a expression among IFN-γ+ CD4+ and IFN-γ+ CD8+ T cells upon pL-
Tag, PHA and irrelevant peptides (HIV) stimulation. Data were reported as fluorescence index (FI) calculated 
by the following formula: (MFI experimental sample – MFI background) / (MFI background) %. Boxes 
represent FI of CD107a staining among CD4+ and CD8+ T cells of four and three PCa patients, respectively. 
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Figure II - 10 Cognate peptide recognitions within CD4+ and CD8+ T cell cultures 
BK1 L-Tag27-41, BK4 L-Tag172-185, BK6 L-Tag212-226 and BK10 L-Tag531-545 specific T cells reactivation after pL-
Tag in vitro sensitization of 3 PCa and 1 HD are represented by dotted gray histograms. Data were reported 
as IFN-γ gene relative expression in peptide triggered cells as compared to baseline generated by HIV 
peptides-pool stimulated counterparts. An arbitrary cut-off (dotted line) was set at 2-fold. 
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Figure II - 11 L-Tag peptides-specific T-cell polyclones recognize peptide-pulsed autologous dendritic 
cells and exert cytotoxicity 
L-Tag-specific T-cell polyclones (three CD4+ and one CD8+) from PCa-196, PCa-226 and HD-GS were 
incubated with autologous mature dendritic cells (IFNDCs) pulsed with either respective specific peptides or an 
irrelevant peptide (HCMV pp65340-355 for CD4+ T-cell polyclones and HCMV pp65495-503 CD8+ T-cell polyclone).  
(A) Cytotoxicity was measured in a LDH release assay. One representative experiment of two is shown. 
(B) Expression analysis of genes encoding cytolytic effector molecules in L-Tag-specific T-cell polyclones. 
Data are reported as relative gene expression of peptide-specific T-cell polyclones as compared to stimulation 
with an irrelevant peptide (HCMV pp65340-355 for CD4+ T-cell polyclones and HCMV pp65495-503 CD8+ T-cell 
polyclone). An arbitrary cut-off (dotted line) was set at 2-fold. 
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5. Discussion 
The evaluation and characterization of HLA-restricted epitope-specific memory T 
Iymphocyte reactivity is an important step for the development of peptide-based 
immunotherapy for viral and tumor diseases. Our previous data support the concept that the 
ex vivo reactivation, and concomitant in vitro expansion, of memory T Iymphocytes using 
single peptides or peptide-pools derived from viral antigens responsible for humoral 
responsiveness in either patients or healthy individuals infected with viruses encoding the 
cognate antigens, can effectively generate peptide-specific cytotoxic T Iymphocyte (CTL) 
exerting immune activities in same subjects (Provenzano, Mocellin et al. 2003). Particularly, 
our previous results also state that specific HLA-A*0201-restricted peptides from 
polyomavirus BK L-Tag can efficiently be used to test immune responses in either HLA-
A*0201+ BKV seropositive prostate cancer patients and HLA-A*0201+ non-age, gender-
matched controls (Provenzano, Bracci et al. 2006; Sais, Wyler et al., 2009).  
Despite bioinformatics-based methodologies for epitope mapping are less effective 
than approaches that use overlapping peptide-pools, the employment of several algorithms 
taking into account different features, such as peptide cleavage and MHC binding affinities, 
would overcome the problem of identifying immunogenic peptides across a wide range of 
MHC specificity. Indeed, in our experience, correlations between in silico predictions and 
peptide-induced immune responses, as analyzed by cytokine gene expression and cytotoxic 
T cell activity, ensures the identification of a substantial number of naturally processed 
antigenic peptides beyond HLA specificities (Provenzano, Sais et al. 2009).  
As first screening, we proposed here the selection of 15-20mer peptides within BKV L-
Tag by combining in silico predictions and cytokine gene expression profiling (qRT-PCR) 
(Provenzano, Mocellin et al. 2002; Provenzano, Bracci et al. 2006). The simultaneous 
analysis of genes encoding proinflammatory (IFN-y, TNF-α, IL2) and immune regulatory 
(IL10, IL4, TGF-ß) cytokine patterns is informative about the nature of cellular immune 
responses elicited by candidate immunogenic peptides (Provenzano, Bracci et al. 2006, 
Sais, Wyler et al., 2009). We thus tested the ability of L-Tag peptides to strongly elicit CD4+ 
and CD8+ responses in prostate cancer patients (PCa), irrespective of specific HLA 
associations, in order to define the level of immunogenicity of these sequences in pre-early 
and early stages of the disease. Our intent was to investigate quantitative and qualitative 
features of CD4+ and CD8+ T cells responses against BKV L-Tag, as differentially 
detectable in BKV seronegative/positive PCa patients, and to compare them to that of both 
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gender- and age-matched BPH patients and gender- but non-age-matched healthy donors 
(HDs). In addition, we also aimed to confirm the evidence that polyfunctional CD4+ T cells 
have a direct crucial role in the control of viral infection (van de Berg, van Leeuwen et al. 
2008; Zhou, Sharma et al. 2007).  
We found that four out of the 11 peptides selected were able: i) to reactivate effector-
memory CD4+ and CD8+ T cells from cancer patients showing an impaired pro-inflammatory 
cytokine (IFN-y and TNF-a) response upon L-Tag peptide pool stimulation, as reported 
before (Sais, Wyler et al. under review; Section 3.3); ii) to generate peptide specific CTL 
polyclones with functional features (degranulation of Iytic machinery components and 
cytotoxic prolife) from single IFN-y secreting T cells, able in turn to exert a Iytic activity on 
cognate peptide-loaded mature DC (mDC) in either BKV seropositive prostate cancer 
patients or healthy donors; iii) do not generate CTLs with an exhausted profile (PD-1) upon 
rounds of stimulations with BKV L-Tag, since chronic infection specifically up-regulates PD-1 
in antigen-specific T cells (Day, Kaufmann et al. 2006) and its expression correlates with the 
functional impairment of those T cells (Barber, Wherry et al. 2006).  
Considering both algorithm analysis and HLA typing carried out on accrued donors and 
patients, we also tempted to restrict HLA class I and/or class II alleles to the selected 
peptides. Despite the limited number of tests reported here, we were able to assign at least 
one HLA association to each peptide. However, further studies are needed to 
unquestionably assign HLA class I and II specific restrictions.  
 The analysis of BKV specific immune response in prostate cancer patients has 
required the use of multiple antigenic peptides. The large panel of specific peptides which 
encompass the entire antigen and that was under consideration in this study should have 
ensured a thorough evaluation of L-Tag specific responsiveness.  
The future administration (systemic or local) of the four BKV L-Tag selected peptides 
using a co-stimulatory-molecules-enhanced recombinant Vaccinia Virus (rW) would 
ameliorate the BKV L-Tag T cell immune response in prostate cancer patients and increase 
the number of non-professional antigen presenting cells that could be identified as targets in 
the site of tumor growth (Adamina, Rosenthal et al. 2010). In addition, boosting BKV peptide-
specific CTL responses might be envisaged either for the treatment of prostate cancer 
patients or as preventive procedure in individuals at risk of developing prostate cancer. The 
vaccination with rW encoding immunogenic peptides avoids the contrived administration of 
adjuvant to enhance peptide activity and to prevent peptide degradation by membrane and 
soluble enzymes expressed by antigen presenting cells microenvironment. (Cavazza, 
Adamina et al. 2004; Nagorsen, Servis et al. 2004)  
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The implementation of these studies might set the stage for original controlled 
investigations on mechanisms allowing BKV involvement in prostate cancers from active 
immune responses identifiable at early stages of prostate cancer and might provide sound 
scientific bases for the application of a wide range MHC peptide-vaccination in either 
preventive or therapeutic settings.  
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